

Form **990**
Department of the Treasury
Internal Revenue Service

Return of Organization Exempt From Income Tax

Under section 501(c), 527, or 4947(a)(1) of the Internal Revenue Code (except private foundations)

Do not enter social security numbers on this form as it may be made public.

Go to www.irs.gov/Form990 for instructions and the latest information.

OMB No. 1545-0047
2019
Open to Public Inspection

A For the **2019** calendar year, or tax year beginning **01-01-2019**, and ending **12-31-2019**

B Check if applicable:
 Address change
 Name change
 Initial return
 Final return/terminated
 Amended return
 Application pending

C Name of organization
NEW YORK GENOME CENTER INC

% NANCY KONG
Doing business as

Number and street (or P.O. box if mail is not delivered to street address) Room/suite
101 AVENUE OF THE AMERICAS Suite 7T

City or town, state or province, country, and ZIP or foreign postal code
NEW YORK, NY 10013

D Employer identification number
80-0631734

E Telephone number
(646) 977-7000

G Gross receipts \$ 45,525,304

F Name and address of principal officer:
TOM MANIATIS
101 AVENUE OF THE AMERICAS
NEW YORK, NY 10013

H(a) Is this a group return for subordinates? Yes No

H(b) Are all subordinates included? Yes No
If "No," attach a list. (see instructions)

H(c) Group exemption number ▶

I Tax-exempt status: 501(c)(3) 501(c) () ◀ (insert no.) 4947(a)(1) or 527

J Website: ▶ www.nygenome.org

K Form of organization: Corporation Trust Association Other ▶

L Year of formation: 2010 **M** State of legal domicile: DE

Part I Summary

1 Briefly describe the organization's mission or most significant activities:
NEW YORK GENOME CENTER (NYGC) IS AN INDEPENDENT, NONPROFIT ACADEMIC RESEARCH INSTITUTION DEDICATED TO GENOMIC DISCOVERY TO ADVANCE HUMAN HEALTH.

2 Check this box if the organization discontinued its operations or disposed of more than 25% of its net assets.

3 Number of voting members of the governing body (Part VI, line 1a)	3	25
4 Number of independent voting members of the governing body (Part VI, line 1b)	4	23
5 Total number of individuals employed in calendar year 2019 (Part V, line 2a)	5	216
6 Total number of volunteers (estimate if necessary)	6	23
7a Total unrelated business revenue from Part VIII, column (C), line 12	7a	1,967,480
7b Net unrelated business taxable income from Form 990-T, line 39	7b	-609,504

	Prior Year	Current Year
8 Contributions and grants (Part VIII, line 1h)	115,038,771	32,878,926
9 Program service revenue (Part VIII, line 2g)	13,156,320	9,402,354
10 Investment income (Part VIII, column (A), lines 3, 4, and 7d)	-14,680	174,909
11 Other revenue (Part VIII, column (A), lines 5, 6d, 8c, 9c, 10c, and 11e)	268,539	-211,744
12 Total revenue—add lines 8 through 11 (must equal Part VIII, column (A), line 12)	128,448,950	42,244,445
13 Grants and similar amounts paid (Part IX, column (A), lines 1-3)	1,300,475	1,899,777
14 Benefits paid to or for members (Part IX, column (A), line 4)	0	0
15 Salaries, other compensation, employee benefits (Part IX, column (A), lines 5-10)	28,154,290	28,935,750
16a Professional fundraising fees (Part IX, column (A), line 11e)	58,590	129,829
b Total fundraising expenses (Part IX, column (D), line 25) ▶ 1,124,071		
17 Other expenses (Part IX, column (A), lines 11a-11d, 11f-24e)	55,044,830	49,234,412
18 Total expenses. Add lines 13-17 (must equal Part IX, column (A), line 25)	84,558,185	80,199,768
19 Revenue less expenses. Subtract line 18 from line 12	43,890,765	-37,955,323

	Beginning of Current Year	End of Year
20 Total assets (Part X, line 16)	148,772,470	97,126,046
21 Total liabilities (Part X, line 26)	63,342,890	49,651,789
22 Net assets or fund balances. Subtract line 21 from line 20	85,429,580	47,474,257

Part II Signature Block

Under penalties of perjury, I declare that I have examined this return, including accompanying schedules and statements, and to the best of my knowledge and belief, it is true, correct, and complete. Declaration of preparer (other than officer) is based on all information of which preparer has any knowledge.

Sign Here

Signature of officer: *****
Date: 2020-11-12

NANCY KONG DIRECTOR, FINANCE
Type or print name and title

Paid Preparer Use Only

Print/Type preparer's name: _____ Preparer's signature: _____ Date: 2020-11-11 Check if self-employed PTIN: P01249521

Firm's name: ▶ KPMG LLP Firm's EIN: _____

Firm's address: ▶ 345 Park Avenue Phone no. (212) 758-9700
New York, NY 101540102

May the IRS discuss this return with the preparer shown above? (see instructions) Yes No

Part III Statement of Program Service Accomplishments

Check if Schedule O contains a response or note to any line in this Part III

1 Briefly describe the organization's mission:

OPERATE A STATE-OF-THE-ART, WORLD-CLASS GENOMIC RESEARCH CENTER THAT CREATES AND USES ADVANCED GENOMICS TO UNDERSTAND THE GENETIC BASIS OF DISEASE. FOR MORE INFORMATION, SEE SCHEDULE O.

2 Did the organization undertake any significant program services during the year which were not listed on the prior Form 990 or 990-EZ? Yes No

If "Yes," describe these new services on Schedule O.

3 Did the organization cease conducting, or make significant changes in how it conducts, any program services? Yes No

If "Yes," describe these changes on Schedule O.

4 Describe the organization's program service accomplishments for each of its three largest program services, as measured by expenses. Section 501(c)(3) and 501(c)(4) organizations are required to report the amount of grants and allocations to others, the total expenses, and revenue, if any, for each program service reported.

4a (Code:) (Expenses \$ 60,802,228 including grants of \$ 1,899,777) (Revenue \$ 8,140,024)
See Additional Data

4b (Code:) (Expenses \$ 3,801,044 including grants of \$) (Revenue \$ 1,262,330)
See Additional Data

4c (Code:) (Expenses \$ including grants of \$) (Revenue \$)

4d Other program services (Describe in Schedule O.)
(Expenses \$ including grants of \$) (Revenue \$)

4e Total program service expenses ▶ 64,603,272

Part IV Checklist of Required Schedules

Table with 3 columns: Question ID, Question Text, and Yes/No response. Rows include questions 1 through 21, with sub-questions a-f for questions 10-12. Questions cover topics like political activities, lobbying, donor funds, conservation easements, and financial reporting.

Part IV Checklist of Required Schedules (continued)

Table with 3 main columns: Question, Yes, No. Rows 22-38 covering various organizational requirements and schedules.

Part V Statements Regarding Other IRS Filings and Tax Compliance

Check if Schedule O contains a response or note to any line in this Part V []

Table with 3 main columns: Question, Yes, No. Rows 1a-1c regarding Form 1096, Forms W-2G, and backup withholding rules.

Part VI Governance, Management, and Disclosure For each "Yes" response to lines 2 through 7b below, and for a "No" response to lines 8a, 8b, or 10b below, describe the circumstances, processes, or changes in Schedule O. See instructions. Check if Schedule O contains a response or note to any line in this Part VI



Section A. Governing Body and Management

Table with 3 columns: Question, Yes, No. Rows include: 1a Enter the number of voting members of the governing body at the end of the tax year (25); 1b Enter the number of voting members included in line 1a, above, who are independent (23); 2 Did any officer, director, trustee, or key employee have a family relationship or a business relationship with any other officer, director, trustee, or key employee? (No); 3 Did the organization delegate control over management duties customarily performed by or under the direct supervision of officers, directors or trustees, or key employees to a management company or other person? (No); 4 Did the organization make any significant changes to its governing documents since the prior Form 990 was filed? (No); 5 Did the organization become aware during the year of a significant diversion of the organization's assets? (No); 6 Did the organization have members or stockholders? (Yes); 7a Did the organization have members, stockholders, or other persons who had the power to elect or appoint one or more members of the governing body? (Yes); 7b Are any governance decisions of the organization reserved to (or subject to approval by) members, stockholders, or persons other than the governing body? (No); 8 Did the organization contemporaneously document the meetings held or written actions undertaken during the year by the following: 8a The governing body? (Yes); 8b Each committee with authority to act on behalf of the governing body? (Yes); 9 Is there any officer, director, trustee, or key employee listed in Part VII, Section A, who cannot be reached at the organization's mailing address? (No)

Section B. Policies (This Section B requests information about policies not required by the Internal Revenue Code.)

Table with 3 columns: Question, Yes, No. Rows include: 10a Did the organization have local chapters, branches, or affiliates? (No); 10b If "Yes," did the organization have written policies and procedures governing the activities of such chapters, affiliates, and branches to ensure their operations are consistent with the organization's exempt purposes?; 11a Has the organization provided a complete copy of this Form 990 to all members of its governing body before filing the form? (Yes); 11b Describe in Schedule O the process, if any, used by the organization to review this Form 990.; 12a Did the organization have a written conflict of interest policy? (Yes); 12b Were officers, directors, or trustees, and key employees required to disclose annually interests that could give rise to conflicts? (Yes); 12c Did the organization regularly and consistently monitor and enforce compliance with the policy? (Yes); 13 Did the organization have a written whistleblower policy? (Yes); 14 Did the organization have a written document retention and destruction policy? (Yes); 15 Did the process for determining compensation of the following persons include a review and approval by independent persons, comparability data, and contemporaneous substantiation of the deliberation and decision? 15a The organization's CEO, Executive Director, or top management official (No); 15b Other officers or key employees of the organization (Yes); 16a Did the organization invest in, contribute assets to, or participate in a joint venture or similar arrangement with a taxable entity during the year? (No); 16b If "Yes," did the organization follow a written policy or procedure requiring the organization to evaluate its participation in joint venture arrangements under applicable federal tax law, and take steps to safeguard the organization's exempt status with respect to such arrangements?

Section C. Disclosure

Table with 3 columns: Question, Yes, No. Rows include: 17 List the states with which a copy of this Form 990 is required to be filed (AL, AK, AR, CA, CO, CT, FL, GA, HI, IL, KS, KY, LA, ME, MD, MA, MI, MN, MS, MO, NH, NJ, NM, NY, NC, ND, OH, OK, OR, PA, RI, SC, TN, UT, VA, WA, WV, WI); 18 Section 6104 requires an organization to make its Form 1023 (or 1024-A if applicable), 990, and 990-T (501(c)(3)s only) available for public inspection. Indicate how you made these available. Check all that apply. [] Own website [] Another's website [x] Upon request [] Other (explain in Schedule O); 19 Describe in Schedule O whether (and if so, how) the organization made its governing documents, conflict of interest policy, and financial statements available to the public during the tax year.; 20 State the name, address, and telephone number of the person who possesses the organization's books and records: NANCY KONG 101 AVENUE OF THE AMERICAS 7TH FLO NEW YORK, NY 10013 (646) 977-7154

Part VIII Statement of Revenue

Check if Schedule O contains a response or note to any line in this Part VIII

		(A) Total revenue	(B) Related or exempt function revenue	(C) Unrelated business revenue	(D) Revenue excluded from tax under sections 512 - 514
Contributions, Gifts, Grants and Other Similar Amounts	1a Federated campaigns	1a			
	b Membership dues	1b	3,135,000		
	c Fundraising events	1c			
	d Related organizations	1d			
	e Government grants (contributions)	1e	18,990,433		
	f All other contributions, gifts, grants, and similar amounts not included above	1f	10,753,493		
	g Noncash contributions included in lines 1a - 1f:\$	1g	0		
	h Total. Add lines 1a-1f		32,878,926		

Program Service Revenue			(A) Total revenue	(B) Related or exempt function revenue	(C) Unrelated business revenue	(D) Revenue excluded from tax under sections 512 - 514
		Business Code				
2a RESEARCH SEQUENCING		541700	8,140,024	6,172,544	1,967,480	
b CLINICAL SEQUENCING		541700	1,262,330	1,262,330		
c						
d						
e						
f All other program service revenue.						
g Total. Add lines 2a-2f.			9,402,354			

Other Revenue			(A) Total revenue	(B) Related or exempt function revenue	(C) Unrelated business revenue	(D) Revenue excluded from tax under sections 512 - 514
3 Investment income (including dividends, interest, and other similar amounts)			174,909			174,909
4 Income from investment of tax-exempt bond proceeds			0			
5 Royalties			636,409			636,409
6a Gross rents	6a	(i) Real	2,394,657			
		(ii) Personal				
	b Less: rental expenses	6b	3,280,859			
	c Rental income or (loss)	6c	-886,202	0		
d Net rental income or (loss)			-886,202			-886,202
7a Gross amount from sales of assets other than inventory	7a	(i) Securities				
		(ii) Other				
	b Less: cost or other basis and sales expenses	7b				
	c Gain or (loss)	7c				
d Net gain or (loss)			0			
8a Gross income from fundraising events (not including \$ _____ of contributions reported on line 1c). See Part IV, line 18	8a		0			
		b Less: direct expenses	8b	0		
	c Net income or (loss) from fundraising events			0		
9a Gross income from gaming activities. See Part IV, line 19	9a		0			
		b Less: direct expenses	9b	0		
	c Net income or (loss) from gaming activities			0		
10a Gross sales of inventory, less returns and allowances	10a		0			
		b Less: cost of goods sold	10b	0		
	c Net income or (loss) from sales of inventory			0		
Miscellaneous Revenue		Business Code				
11a EVENT SPACE REVENUE		900099	29,800			29,800
b OTHER REVENUE		900099	8,249			8,249
c						
d All other revenue						
e Total. Add lines 11a-11d			38,049			
12 Total revenue. See instructions			42,244,445	7,434,874	1,967,480	-36,835

Part IX Statement of Functional Expenses

Section 501(c)(3) and 501(c)(4) organizations must complete all columns. All other organizations must complete column (A).

Check if Schedule O contains a response or note to any line in this Part IX

Do not include amounts reported on lines 6b, 7b, 8b, 9b, and 10b of Part VIII.	(A) Total expenses	(B) Program service expenses	(C) Management and general expenses	(D) Fundraising expenses
1 Grants and other assistance to domestic organizations and domestic governments. See Part IV, line 21	1,762,476	1,762,476		
2 Grants and other assistance to domestic individuals. See Part IV, line 22	0			
3 Grants and other assistance to foreign organizations, foreign governments, and foreign individuals. See Part IV, lines 15 and 16.	137,301	137,301		
4 Benefits paid to or for members	0			
5 Compensation of current officers, directors, trustees, and key employees	6,845,379	2,303,466	4,115,224	426,689
6 Compensation not included above, to disqualified persons (as defined under section 4958(f)(1)) and persons described in section 4958(c)(3)(B)	135,071	135,071		
7 Other salaries and wages	16,738,434	12,674,995	3,851,744	211,695
8 Pension plan accruals and contributions (include section 401 (k) and 403(b) employer contributions)	1,005,299	684,911	300,550	19,838
9 Other employee benefits	2,466,292	1,536,505	907,777	22,010
10 Payroll taxes	1,745,275	1,277,011	432,710	35,554
11 Fees for services (non-employees):				
a Management	0			
b Legal	333,165		333,165	
c Accounting	137,269		137,269	
d Lobbying	45,250			45,250
e Professional fundraising services. See Part IV, line 17	129,829			129,829
f Investment management fees	0			
g Other (If line 11g amount exceeds 10% of line 25, column (A) amount, list line 11g expenses on Schedule O)	2,271,464	1,884,934	386,530	
12 Advertising and promotion	0			
13 Office expenses	515,783	139,845	374,710	1,228
14 Information technology	2,405,819	2,157,843	247,976	
15 Royalties	224,718	224,718		
16 Occupancy	13,114,006	11,406,849	1,550,910	156,247
17 Travel	319,657	246,721	67,529	5,407
18 Payments of travel or entertainment expenses for any federal, state, or local public officials	0			
19 Conferences, conventions, and meetings	316,374	137,225	167,740	11,409
20 Interest	841,753	635,620	197,279	8,854
21 Payments to affiliates	0			
22 Depreciation, depletion, and amortization	9,680,141	8,985,905	649,624	44,612
23 Insurance	461,374		461,374	
24 Other expenses. Itemize expenses not covered above (List miscellaneous expenses in line 24e. If line 24e amount exceeds 10% of line 25, column (A) amount, list line 24e expenses on Schedule O.)				
a DIRECT COST OF SEQUENCING	15,467,596	15,467,596		
b RESEARCH & CLIA	2,316,257	2,316,257		
c RECRUITMENT	381,455	336,006	45,449	
d ALL OTHER EXPENSE	402,331	152,017	244,865	5,449
e All other expenses				
25 Total functional expenses. Add lines 1 through 24e	80,199,768	64,603,272	14,472,425	1,124,071
26 Joint costs. Complete this line only if the organization reported in column (B) joint costs from a combined educational campaign and fundraising solicitation. Check here <input type="checkbox"/> if following SOP 98-2 (ASC 958-720).				

Part X Balance Sheet

Check if Schedule O contains a response or note to any line in this Part IX

		(A) Beginning of year		(B) End of year
Assets	1 Cash—non-interest-bearing	7,834,528	1	11,828,949
	2 Savings and temporary cash investments	0	2	0
	3 Pledges and grants receivable, net	51,450,236	3	6,037,230
	4 Accounts receivable, net	7,070,357	4	5,125,099
	5 Loans and other payables to any current or former officer, director, trustee, key employee, creator or founder, substantial contributor, or 35% controlled entity or family member of any of these persons	0	5	0
	6 Loans and other receivables from other disqualified persons (as defined under section 4958(f)(1)), and persons described in section 4958(c)(3)(B)	0	6	0
	7 Notes and loans receivable, net	0	7	0
	8 Inventories for sale or use	3,402,687	8	2,964,323
	9 Prepaid expenses and deferred charges	3,120,795	9	3,956,650
	10a Land, buildings, and equipment: cost or other basis. Complete Part VI of Schedule D	10a 129,908,990		
	b Less: accumulated depreciation	10b 72,237,589	65,127,906	10c 57,671,401
	11 Investments—publicly traded securities	0	11	0
	12 Investments—other securities. See Part IV, line 11	0	12	0
	13 Investments—program-related. See Part IV, line 11	0	13	0
	14 Intangible assets	0	14	0
	15 Other assets. See Part IV, line 11	10,765,961	15	9,542,394
16 Total assets. Add lines 1 through 15 (must equal line 34)	148,772,470	16	97,126,046	
Liabilities	17 Accounts payable and accrued expenses	11,850,899	17	6,109,365
	18 Grants payable	0	18	0
	19 Deferred revenue	5,322,019	19	10,610,221
	20 Tax-exempt bond liabilities	0	20	0
	21 Escrow or custodial account liability. Complete Part IV of Schedule D	0	21	0
	22 Loans and other payables to any current or former officer, director, trustee, key employee, creator or founder, substantial contributor, or 35% controlled entity or family member of any of these persons	0	22	0
	23 Secured mortgages and notes payable to unrelated third parties	4,757,610	23	2,144,347
	24 Unsecured notes and loans payable to unrelated third parties	14,569,000	24	4,820,000
	25 Other liabilities (including federal income tax, payables to related third parties, and other liabilities not included on lines 17 - 24). Complete Part X of Schedule D	26,843,362	25	25,967,856
	26 Total liabilities. Add lines 17 through 25	63,342,890	26	49,651,789
Net Assets or Fund Balances	Organizations that follow FASB ASC 958, check here <input checked="" type="checkbox"/> and complete lines 27, 28, 32, and 33.			
	27 Net assets without donor restrictions	33,045,706	27	40,350,629
	28 Net assets with donor restrictions	52,383,874	28	7,123,628
	Organizations that do not follow FASB ASC 958, check here <input type="checkbox"/> and complete lines 29 through 33.			
	29 Capital stock or trust principal, or current funds		29	
	30 Paid-in or capital surplus, or land, building or equipment fund		30	
	31 Retained earnings, endowment, accumulated income, or other funds		31	
32 Total net assets or fund balances	85,429,580	32	47,474,257	
33 Total liabilities and net assets/fund balances	148,772,470	33	97,126,046	

Part XI Reconciliation of Net Assets

Check if Schedule O contains a response or note to any line in this Part XI

1	Total revenue (must equal Part VIII, column (A), line 12)	1	42,244,445
2	Total expenses (must equal Part IX, column (A), line 25)	2	80,199,768
3	Revenue less expenses. Subtract line 2 from line 1	3	-37,955,323
4	Net assets or fund balances at beginning of year (must equal Part X, line 33, column (A))	4	85,429,580
5	Net unrealized gains (losses) on investments	5	
6	Donated services and use of facilities	6	
7	Investment expenses	7	
8	Prior period adjustments	8	
9	Other changes in net assets or fund balances (explain in Schedule O)	9	
10	Net assets or fund balances at end of year. Combine lines 3 through 9 (must equal Part X, line 33, column (B))	10	47,474,257

Part XII Financial Statements and Reporting

Check if Schedule O contains a response or note to any line in this Part XII

- 1** Accounting method used to prepare the Form 990: Cash Accrual Other _____
 If the organization changed its method of accounting from a prior year or checked "Other," explain in Schedule O.
- 2a** Were the organization's financial statements compiled or reviewed by an independent accountant?
 If 'Yes,' check a box below to indicate whether the financial statements for the year were compiled or reviewed on a separate basis, consolidated basis, or both:
 Separate basis Consolidated basis Both consolidated and separate basis
- b** Were the organization's financial statements audited by an independent accountant?
 If 'Yes,' check a box below to indicate whether the financial statements for the year were audited on a separate basis, consolidated basis, or both:
 Separate basis Consolidated basis Both consolidated and separate basis
- c** If "Yes," to line 2a or 2b, does the organization have a committee that assumes responsibility for oversight of the audit, review, or compilation of its financial statements and selection of an independent accountant?
 If the organization changed either its oversight process or selection process during the tax year, explain in Schedule O.
- 3a** As a result of a federal award, was the organization required to undergo an audit or audits as set forth in the Single Audit Act and OMB Circular A-133?
- b** If "Yes," did the organization undergo the required audit or audits? If the organization did not undergo the required audit or audits, explain why in Schedule O and describe any steps taken to undergo such audits.

	Yes	No
2a		No
2b	Yes	
2c	Yes	
3a	Yes	
3b	Yes	

Additional Data

Software ID:

Software Version:

EIN: 80-0631734

Name: NEW YORK GENOME CENTER INC

Form 990 (2019)

Form 990, Part III, Line 4a:

RESEARCH AND RESEARCH SEQUENCING - NYGC'S RESEARCH SCIENTISTS AND FACULTY ARE EXPLORING GENOMIC CONTRIBUTORS TO HUMAN DISEASE, BOTH IN THEIR OWN PROJECTS AND THROUGH COLLABORATIONS. NYGC RESEARCHERS HAVE PROJECTS UNDERWAY IN CANCER, INCLUDING LUNG, LIVER, BREAST AND MELANOMA, A MULTI-SITE VERY RARE CANCER PROJECT AND A LARGE COLLABORATIVE PROJECT STUDYING CANCER IN UNDERSERVED POPULATIONS IN NYC; NEURODEGENERATIVE DISEASES, INCLUDING ALS AND DEMENTIA; AND NEUROPSYCHIATRIC DISEASES, FOCUSING ON AUTISM, AMONG OTHERS. FOR MORE INFORMATION SEE SCHEDULE O.

Form 990, Part III, Line 4b:

CLINICAL SEQUENCING - NYGC IS AUTHORIZED BY THE NEW YORK STATE DEPARTMENT OF HEALTH TO OFFER THE FOLLOWING APPROVED CLINICAL TESTS THROUGH ITS CLEP/CLIA-CERTIFIED CLINICAL LABORATORY: CONSTITUTIONAL WHOLE GENOME SEQUENCING FOR UNDIAGNOSED DISEASE, CONSTITUTIONAL WHOLE GENOME SEQUENCING FOR PREDISPOSITIONAL GENETIC SCREENING, ONCOLOGY WHOLE GENOME AND TRANSCRIPTOME SEQUENCING, CONSTITUTIONAL WHOLE EXOME SEQUENCING, TARGETED VARIANT TESTING USING SANGER SEQUENCING, SMASH GENOMIC ASSAY, OFF-SITE MSK-IMPACT SEQUENCING, AND SEQUENCING OF PREPARED LIBRARIES FOR MGTL.

Form 990, Part VII - Compensation of Officers, Directors, Trustees, Key Employees, Highest Compensated Employees, and Independent Contractors										
(A) Name and Title	(B) Average hours per week (list any hours for related organizations below dotted line)	(C) Position (do not check more than one box, unless person is both an officer and a director/trustee)						(D) Reportable compensation from the organization (W- 2/1099-MISC)	(E) Reportable compensation from related organizations (W- 2/1099-MISC)	(F) Estimated amount of other compensation from the organization and related organizations
		Individual trustee or director	Institutional Trustee	Officer	Key employee	Highest compensated employee	Former			
CHERYL A MOORE PRESIDENT & COO	40.0 0.0	X		X				1,840,182	0	218,228
Tom Maniatis PHD SCIENTIFIC DIR & CEO	40.0 0.0	X		X				582,430	0	0
ELIZABETH BROOKS O'BRI VICE PRESIDENT & GEN. COUNSEL	40.0 0.0			X				419,097	0	44,284
CAROL ASHE CHIEF BUSINESS OFFICER	40.0 0.0				X			414,579	0	14,117
KATHLEEN MCGOVERN KEAR VICE PRESIDENT, DEV'T & COMM	40.0 0.0				X			399,020	0	27,668
ANA LUCIA BASTIANI-POS SVP, Finance and Admin	40.0 0.0				X			386,106	0	17,268
SOREN GERMER SVP, Genome Technologies	40.0 0.0				X			308,155	0	29,347
SHAILAJA GARGEYA SENIOR DIR, SOFTWARE ENGINEER	40.0 0.0					X		316,290	0	16,877
TOBY BLOOM Former Key Employee	40.0 0.0						X	301,520	0	17,821
CHARLES GAGNON SENIOR DIR, IT INFRASTRUCTURE	40.0 0.0				X			273,903	0	41,224

Form 990, Part VII - Compensation of Officers, Directors, Trustees, Key Employees, Highest Compensated Employees, and Independent Contractors										
(A) Name and Title	(B) Average hours per week (list any hours for related organizations below dotted line)	(C) Position (do not check more than one box, unless person is both an officer and a director/trustee)						(D) Reportable compensation from the organization (W- 2/1099-MISC)	(E) Reportable compensation from related organizations (W- 2/1099-MISC)	(F) Estimated amount of other compensation from the organization and related organizations
		Individual trustee or director	Institutional Trustee	Officer	Key employee	Highest compensated employee	Former			
DAYNA M OSCHWALD chief of staff, office sci dir	40.0 0.0					X		251,680	0	23,511
CHRISTOPHER PHIFER BLA DIRECTOR, RESEARCH COMPUTING	40.0 0.0					X		206,054	0	35,982
HANNAH GOULDING Senior Director, HR	40.0 0.0					X		213,006	0	10,767
MELISSA PROBER Senior Associate Counsel	40.0 0.0					X		212,663	0	9,801
MICHAEL CHARLES ZODY Scientific Dir, COMP BIOLOGY	40.0 0.0					X		197,824	0	15,975
DAFNA BAR-SAGI PHD DIRECTOR	1.0 0.0	X						0	0	0
RUSSELL L CARSON MBA DIRECTOR & CO-CHAIR	4.0 0.0	X		X				0	0	0
ELI CASDIN DIRECTOR (START 10/31/19)	1.0 0.0	X						0	0	0
DENNIS S CHARNEY MD DIRECTOR	1.0 0.0	X						0	0	0
AUGUSTINE MK CHOI M DIRECTOR	1.0 0.0	X						0	0	0

Form 990, Part VII - Compensation of Officers, Directors, Trustees, Key Employees, Highest Compensated Employees, and Independent Contractors										
(A) Name and Title	(B) Average hours per week (list any hours for related organizations below dotted line)	(C) Position (do not check more than one box, unless person is both an officer and a director/trustee)						(D) Reportable compensation from the organization (W- 2/1099-MISC)	(E) Reportable compensation from related organizations (W- 2/1099-MISC)	(F) Estimated amount of other compensation from the organization and related organizations
		Individual trustee or director	Institutional Trustee	Officer	Key employee	Highest compensated employee	Former			
NICHOLAS DONOFRIO DIRECTOR	1.0 0.0	X						0	0	0
JOHN B EHRENKRANZ DIRECTOR	1.0 0.0	X						0	0	0
ANTHONY B EVNIN PHD DIRECTOR	1.0 0.0	X						0	0	0
LEE GOLDMAN MD MPH DIRECTOR	1.0 0.0	X						0	0	0
JOHN HAVENS DIRECTOR (THROUGH 2/26/19)	1.0 0.0	X						0	0	0
WESLIE R JANEWAY DIRECTOR	1.0 0.0	X						0	0	0
KENNETH KAUSHANSKY MD DIRECTOR (START 10/31/19)	1.0 0.0	X						0	0	0
RICHARD P LIFTON MD DIRECTOR	1.0 0.0	X						0	0	0
EDISON T LIU MD DIRECTOR	1.0 0.0	X						0	0	0
HERB PARDES MD DIRECTOR & VICE CHAIR	1.0 0.0	X						0	0	0

Form 990, Part VII - Compensation of Officers, Directors, Trustees, Key Employees, Highest Compensated Employees, and Independent Contractors

(A) Name and Title	(B) Average hours per week (list any hours for related organizations below dotted line)	(C) Position (do not check more than one box, unless person is both an officer and a director/trustee)						(D) Reportable compensation from the organization (W- 2/1099-MISC)	(E) Reportable compensation from related organizations (W- 2/1099-MISC)	(F) Estimated amount of other compensation from the organization and related organizations
		Individual trustee or director	Institutional Trustee	Officer	Key employee	Highest compensated employee	Former			
FRANK E RICHARDSON M DIRECTOR	1.0 0.0	X						0	0	0
IVAN G SEIDENBERG MB DIRECTOR & CO-CHAIR	4.0 0.0	X		X				0	0	0
FRANK V SICA DIRECTOR / COMMITTEE CHAIR	1.0 0.0	X						0	0	0
JIM SIMONS PHD DIRECTOR	1.0 0.0	X						0	0	0
STEVEN D SINGER ESQ DIRECTOR	1.0 0.0	X						0	0	0
SAMUEL L STANLEY JR DIRECTOR (THROUGH 7/31/19)	1.0 0.0	X						0	0	0
BRUCE STILLMAN PHD DIRECTOR	1.0 0.0	X						0	0	0
CRAIG B THOMPSON MD DIRECTOR	1.0 0.0	X						0	0	0
GORDON F TOMASELLI M DIRECTOR	1.0 0.0	X						0	0	0
KEVIN J TRACEY MD DIRECTOR	1.0 0.0	X						0	0	0

SCHEDULE A
(Form 990 or 990-EZ)

Public Charity Status and Public Support
Complete if the organization is a section 501(c)(3) organization or a section 4947(a)(1) nonexempt charitable trust.
▶ Attach to Form 990 or Form 990-EZ.
▶ Go to www.irs.gov/Form990 for instructions and the latest information.

OMB No. 1545-0047
2019
Open to Public Inspection

Department of the Treasury
Internal Revenue Service

Name of the organization
NEW YORK GENOME CENTER INC

Employer identification number
80-0631734

Part I Reason for Public Charity Status (All organizations must complete this part.) See instructions.

The organization is not a private foundation because it is: (For lines 1 through 12, check only one box.)

- 1 A church, convention of churches, or association of churches described in **section 170(b)(1)(A)(i).**
- 2 A school described in **section 170(b)(1)(A)(ii).** (Attach Schedule E (Form 990 or 990-EZ).)
- 3 A hospital or a cooperative hospital service organization described in **section 170(b)(1)(A)(iii).**
- 4 A medical research organization operated in conjunction with a hospital described in **section 170(b)(1)(A)(iii).** Enter the hospital's name, city, and state:
- 5 An organization operated for the benefit of a college or university owned or operated by a governmental unit described in **section 170(b)(1)(A)(iv).** (Complete Part II.)
- 6 A federal, state, or local government or governmental unit described in **section 170(b)(1)(A)(v).**
- 7 An organization that normally receives a substantial part of its support from a governmental unit or from the general public described in **section 170(b)(1)(A)(vi).** (Complete Part II.)
- 8 A community trust described in **section 170(b)(1)(A)(vi).** (Complete Part II.)
- 9 An agricultural research organization described in **170(b)(1)(A)(ix)** operated in conjunction with a land-grant college or university or a non-land grant college of agriculture. See instructions. Enter the name, city, and state of the college or university:
- 10 An organization that normally receives: (1) more than 33 1/3% of its support from contributions, membership fees, and gross receipts from activities related to its exempt functions—subject to certain exceptions, and (2) no more than 33 1/3% of its support from gross investment income and unrelated business taxable income (less section 511 tax) from businesses acquired by the organization after June 30, 1975. See **section 509(a)(2).** (Complete Part III.)
- 11 An organization organized and operated exclusively to test for public safety. See **section 509(a)(4).**
- 12 An organization organized and operated exclusively for the benefit of, to perform the functions of, or to carry out the purposes of one or more publicly supported organizations described in **section 509(a)(1)** or **section 509(a)(2).** See **section 509(a)(3).** Check the box in lines 12a through 12d that describes the type of supporting organization and complete lines 12e, 12f, and 12g.
 - a **Type I.** A supporting organization operated, supervised, or controlled by its supported organization(s), typically by giving the supported organization(s) the power to regularly appoint or elect a majority of the directors or trustees of the supporting organization. **You must complete Part IV, Sections A and B.**
 - b **Type II.** A supporting organization supervised or controlled in connection with its supported organization(s), by having control or management of the supporting organization vested in the same persons that control or manage the supported organization(s). **You must complete Part IV, Sections A and C.**
 - c **Type III functionally integrated.** A supporting organization operated in connection with, and functionally integrated with, its supported organization(s) (see instructions). **You must complete Part IV, Sections A, D, and E.**
 - d **Type III non-functionally integrated.** A supporting organization operated in connection with its supported organization(s) that is not functionally integrated. The organization generally must satisfy a distribution requirement and an attentiveness requirement (see instructions). **You must complete Part IV, Sections A and D, and Part V.**
 - e Check this box if the organization received a written determination from the IRS that it is a Type I, Type II, Type III functionally integrated, or Type III non-functionally integrated supporting organization.
 - f Enter the number of supported organizations _____
 - g Provide the following information about the supported organization(s).

(i) Name of supported organization	(ii) EIN	(iii) Type of organization (described on lines 1- 10 above (see instructions))	(iv) Is the organization listed in your governing document?		(v) Amount of monetary support (see instructions)	(vi) Amount of other support (see instructions)
			Yes	No		
Total						

Part II Support Schedule for Organizations Described in Sections 170(b)(1)(A)(iv) and 170(b)(1)(A)(vi)
 (Complete only if you checked the box on line 5, 7, or 8 of Part I or if the organization failed to qualify under Part III.
 If the organization failed to qualify under the tests listed below, please complete Part III.)

Section A. Public Support

Calendar year (or fiscal year beginning in) ▶	(a) 2015	(b) 2016	(c) 2017	(d) 2018	(e) 2019	(f) Total
1 Gifts, grants, contributions, and membership fees received. (Do not include any "unusual grant.") . . .	61,060,764	94,901,046	70,723,214	115,038,771	32,878,926	374,602,721
2 Tax revenues levied for the organization's benefit and either paid to or expended on its behalf						0
3 The value of services or facilities furnished by a governmental unit to the organization without charge..						0
4 Total. Add lines 1 through 3	61,060,764	94,901,046	70,723,214	115,038,771	32,878,926	374,602,721
5 The portion of total contributions by each person (other than a governmental unit or publicly supported organization) included on line 1 that exceeds 2% of the amount shown on line 11, column (f).						160,330,929
6 Public support. Subtract line 5 from line 4.						214,271,792

Section B. Total Support

Calendar year (or fiscal year beginning in) ▶	(a) 2015	(b) 2016	(c) 2017	(d) 2018	(e) 2019	(f) Total
7 Amounts from line 4.	61,060,764	94,901,046	70,723,214	115,038,771	32,878,926	374,602,721
8 Gross income from interest, dividends, payments received on securities loans, rents, royalties and income from similar sources	268,801	302,728	378,725	2,090,669	3,205,975	6,246,898
9 Net income from unrelated business activities, whether or not the business is regularly carried on						0
10 Other income. Do not include gain or loss from the sale of capital assets (Explain in Part VI.).	116,870	58,024	95,299	104,653	38,049	412,895
11 Total support. Add lines 7 through 10						381,262,514
12 Gross receipts from related activities, etc. (see instructions)					12	101,155,177

13 First five years. If the Form 990 is for the organization's first, second, third, fourth, or fifth tax year as a section 501(c)(3) organization, check this box and **stop here**

Section C. Computation of Public Support Percentage

14 Public support percentage for 2019 (line 6, column (f) divided by line 11, column (f))	14	56.201 %
15 Public support percentage for 2018 Schedule A, Part II, line 14	15	56.486 %

- 16a 33 1/3% support test—2019.** If the organization did not check the box on line 13, and line 14 is 33 1/3% or more, check this box and **stop here.** The organization qualifies as a publicly supported organization
- b 33 1/3% support test—2018.** If the organization did not check a box on line 13 or 16a, and line 15 is 33 1/3% or more, check this box and **stop here.** The organization qualifies as a publicly supported organization
- 17a 10%-facts-and-circumstances test—2019.** If the organization did not check a box on line 13, 16a, or 16b, and line 14 is 10% or more, and if the organization meets the "facts-and-circumstances" test, check this box and **stop here.** Explain in Part VI how the organization meets the "facts-and-circumstances" test. The organization qualifies as a publicly supported organization
- b 10%-facts-and-circumstances test—2018.** If the organization did not check a box on line 13, 16a, 16b, or 17a, and line 15 is 10% or more, and if the organization meets the "facts-and-circumstances" test, check this box and **stop here.** Explain in Part VI how the organization meets the "facts-and-circumstances" test. The organization qualifies as a publicly supported organization
- 18 Private foundation.** If the organization did not check a box on line 13, 16a, 16b, 17a, or 17b, check this box and see instructions

Part III Support Schedule for Organizations Described in Section 509(a)(2)

(Complete only if you checked the box on line 10 of Part I or if the organization failed to qualify under Part II. If the organization fails to qualify under the tests listed below, please complete Part II.)

Section A. Public Support

Calendar year (or fiscal year beginning in) ►	(a) 2015	(b) 2016	(c) 2017	(d) 2018	(e) 2019	(f) Total
1 Gifts, grants, contributions, and membership fees received. (Do not include any "unusual grants.") .						
2 Gross receipts from admissions, merchandise sold or services performed, or facilities furnished in any activity that is related to the organization's tax-exempt purpose						
3 Gross receipts from activities that are not an unrelated trade or business under section 513						
4 Tax revenues levied for the organization's benefit and either paid to or expended on its behalf. . .						
5 The value of services or facilities furnished by a governmental unit to the organization without charge						
6 Total. Add lines 1 through 5						
7a Amounts included on lines 1, 2, and 3 received from disqualified persons						
b Amounts included on lines 2 and 3 received from other than disqualified persons that exceed the greater of \$5,000 or 1% of the amount on line 13 for the year.						
c Add lines 7a and 7b.						
8 Public support. (Subtract line 7c from line 6.)						

Section B. Total Support

Calendar year (or fiscal year beginning in) ►	(a) 2015	(b) 2016	(c) 2017	(d) 2018	(e) 2019	(f) Total
9 Amounts from line 6.						
10a Gross income from interest, dividends, payments received on securities loans, rents, royalties and income from similar sources. . .						
b Unrelated business taxable income (less section 511 taxes) from businesses acquired after June 30, 1975.						
c Add lines 10a and 10b.						
11 Net income from unrelated business activities not included in line 10b, whether or not the business is regularly carried on.						
12 Other income. Do not include gain or loss from the sale of capital assets (Explain in Part VI.)						
13 Total support. (Add lines 9, 10c, 11, and 12.)						

14 First five years. If the Form 990 is for the organization's first, second, third, fourth, or fifth tax year as a section 501(c)(3) organization, check this box and **stop here.**

Section C. Computation of Public Support Percentage

15 Public support percentage for 2019 (line 8, column (f) divided by line 13, column (f))	15	
16 Public support percentage from 2018 Schedule A, Part III, line 15	16	

Section D. Computation of Investment Income Percentage

17 Investment income percentage for 2019 (line 10c, column (f) divided by line 13, column (f))	17	
18 Investment income percentage from 2018 Schedule A, Part III, line 17	18	

19a 33 1/3% support tests—2019. If the organization did not check the box on line 14, and line 15 is more than 33 1/3%, and line 17 is not more than 33 1/3%, check this box and **stop here.** The organization qualifies as a publicly supported organization

b 33 1/3% support tests—2018. If the organization did not check a box on line 14 or line 19a, and line 16 is more than 33 1/3% and line 18 is not more than 33 1/3%, check this box and **stop here.** The organization qualifies as a publicly supported organization

20 Private foundation. If the organization did not check a box on line 14, 19a, or 19b, check this box and see instructions

Part IV Supporting Organizations

(Complete only if you checked a box on line 12 of Part I. If you checked 12a of Part I, complete Sections A and B. If you checked 12b of Part I, complete Sections A and C. If you checked 12c of Part I, complete Sections A, D, and E. If you checked 12d of Part I, complete Sections A and D, and complete Part V.)

Section A. All Supporting Organizations

		Yes	No
1	Are all of the organization's supported organizations listed by name in the organization's governing documents? <i>If "No," describe in Part VI how the supported organizations are designated. If designated by class or purpose, describe the designation. If historic and continuing relationship, explain.</i>		
2	Did the organization have any supported organization that does not have an IRS determination of status under section 509(a)(1) or (2)? <i>If "Yes," explain in Part VI how the organization determined that the supported organization was described in section 509(a)(1) or (2).</i>		
3a	Did the organization have a supported organization described in section 501(c)(4), (5), or (6)? <i>If "Yes," answer (b) and (c) below.</i>		
b	Did the organization confirm that each supported organization qualified under section 501(c)(4), (5), or (6) and satisfied the public support tests under section 509(a)(2)? <i>If "Yes," describe in Part VI when and how the organization made the determination.</i>		
c	Did the organization ensure that all support to such organizations was used exclusively for section 170(c)(2)(B) purposes? <i>If "Yes," explain in Part VI what controls the organization put in place to ensure such use.</i>		
4a	Was any supported organization not organized in the United States ("foreign supported organization")? <i>If "Yes" and if you checked 12a or 12b in Part I, answer (b) and (c) below.</i>		
b	Did the organization have ultimate control and discretion in deciding whether to make grants to the foreign supported organization? <i>If "Yes," describe in Part VI how the organization had such control and discretion despite being controlled or supervised by or in connection with its supported organizations.</i>		
c	Did the organization support any foreign supported organization that does not have an IRS determination under sections 501(c)(3) and 509(a)(1) or (2)? <i>If "Yes," explain in Part VI what controls the organization used to ensure that all support to the foreign supported organization was used exclusively for section 170(c)(2)(B) purposes.</i>		
5a	Did the organization add, substitute, or remove any supported organizations during the tax year? <i>If "Yes," answer (b) and (c) below (if applicable). Also, provide detail in Part VI, including (i) the names and EIN numbers of the supported organizations added, substituted, or removed; (ii) the reasons for each such action; (iii) the authority under the organization's organizing document authorizing such action; and (iv) how the action was accomplished (such as by amendment to the organizing document).</i>		
b	Type I or Type II only. Was any added or substituted supported organization part of a class already designated in the organization's organizing document?		
c	Substitutions only. Was the substitution the result of an event beyond the organization's control?		
6	Did the organization provide support (whether in the form of grants or the provision of services or facilities) to anyone other than (i) its supported organizations, (ii) individuals that are part of the charitable class benefited by one or more of its supported organizations, or (iii) other supporting organizations that also support or benefit one or more of the filing organization's supported organizations? <i>If "Yes," provide detail in Part VI.</i>		
7	Did the organization provide a grant, loan, compensation, or other similar payment to a substantial contributor (defined in section 4958(c)(3)(C)), a family member of a substantial contributor, or a 35% controlled entity with regard to a substantial contributor? <i>If "Yes," complete Part I of Schedule L (Form 990 or 990-EZ) .</i>		
8	Did the organization make a loan to a disqualified person (as defined in section 4958) not described in line 7? <i>If "Yes," complete Part I of Schedule L (Form 990 or 990-EZ).</i>		
9a	Was the organization controlled directly or indirectly at any time during the tax year by one or more disqualified persons as defined in section 4946 (other than foundation managers and organizations described in section 509(a)(1) or (2))? <i>If "Yes," provide detail in Part VI.</i>		
b	Did one or more disqualified persons (as defined in line 9a) hold a controlling interest in any entity in which the supporting organization had an interest? <i>If "Yes," provide detail in Part VI.</i>		
c	Did a disqualified person (as defined in line 9a) have an ownership interest in, or derive any personal benefit from, assets in which the supporting organization also had an interest? <i>If "Yes," provide detail in Part VI.</i>		
10a	Was the organization subject to the excess business holdings rules of section 4943 because of section 4943(f) (regarding certain Type II supporting organizations, and all Type III non-functionally integrated supporting organizations)? <i>If "Yes," answer line 10b below.</i>		
b	Did the organization have any excess business holdings in the tax year? <i>(Use Schedule C, Form 4720, to determine whether the organization had excess business holdings).</i>		

Part IV Supporting Organizations (continued)

		Yes	No
11	Has the organization accepted a gift or contribution from any of the following persons?		
a	A person who directly or indirectly controls, either alone or together with persons described in (b) and (c) below, the governing body of a supported organization?		
b	A family member of a person described in (a) above?		
c	A 35% controlled entity of a person described in (a) or (b) above? <i>If "Yes" to a, b, or c, provide detail in Part VI.</i>		

Section B. Type I Supporting Organizations

		Yes	No
1	Did the directors, trustees, or membership of one or more supported organizations have the power to regularly appoint or elect at least a majority of the organization's directors or trustees at all times during the tax year? <i>If "No," describe in Part VI how the supported organization(s) effectively operated, supervised, or controlled the organization's activities. If the organization had more than one supported organization, describe how the powers to appoint and/or remove directors or trustees were allocated among the supported organizations and what conditions or restrictions, if any, applied to such powers during the tax year.</i>		
2	Did the organization operate for the benefit of any supported organization other than the supported organization(s) that operated, supervised, or controlled the supporting organization? <i>If "Yes," explain in Part VI how providing such benefit carried out the purposes of the supported organization(s) that operated, supervised or controlled the supporting organization.</i>		

Section C. Type II Supporting Organizations

		Yes	No
1	Were a majority of the organization's directors or trustees during the tax year also a majority of the directors or trustees of each of the organization's supported organization(s)? <i>If "No," describe in Part VI how control or management of the supporting organization was vested in the same persons that controlled or managed the supported organization(s).</i>		

Section D. All Type III Supporting Organizations

		Yes	No
1	Did the organization provide to each of its supported organizations, by the last day of the fifth month of the organization's tax year, (i) a written notice describing the type and amount of support provided during the prior tax year, (ii) a copy of the Form 990 that was most recently filed as of the date of notification, and (iii) copies of the organization's governing documents in effect on the date of notification, to the extent not previously provided?		
2	Were any of the organization's officers, directors, or trustees either (i) appointed or elected by the supported organization (s) or (ii) serving on the governing body of a supported organization? <i>If "No," explain in Part VI how the organization maintained a close and continuous working relationship with the supported organization(s).</i>		
3	By reason of the relationship described in (2), did the organization's supported organizations have a significant voice in the organization's investment policies and in directing the use of the organization's income or assets at all times during the tax year? <i>If "Yes," describe in Part VI the role the organization's supported organizations played in this regard.</i>		

Section E. Type III Functionally-Integrated Supporting Organizations

1	Check the box next to the method that the organization used to satisfy the Integral Part Test during the year (see instructions):		
a	<input type="checkbox"/> The organization satisfied the Activities Test. Complete line 2 below.		
b	<input type="checkbox"/> The organization is the parent of each of its supported organizations. Complete line 3 below.		
c	<input type="checkbox"/> The organization supported a governmental entity. Describe in Part VI how you supported a government entity (see instructions)		
2	Activities Test. Answer (a) and (b) below.		
a	Did substantially all of the organization's activities during the tax year directly further the exempt purposes of the supported organization(s) to which the organization was responsive? <i>If "Yes," then in Part VI identify those supported organizations and explain how these activities directly furthered their exempt purposes, how the organization was responsive to those supported organizations, and how the organization determined that these activities constituted substantially all of its activities.</i>	Yes	No
b	Did the activities described in (a) constitute activities that, but for the organization's involvement, one or more of the organization's supported organization(s) would have been engaged in? <i>If "Yes," explain in Part VI the reasons for the organization's position that its supported organization(s) would have engaged in these activities but for the organization's involvement.</i>		
3	Parent of Supported Organizations. Answer (a) and (b) below.		
a	Did the organization have the power to regularly appoint or elect a majority of the officers, directors, or trustees of each of the supported organizations? <i>Provide details in Part VI.</i>		
b	Did the organization exercise a substantial degree of direction over the policies, programs and activities of each of its supported organizations? <i>If "Yes," describe in Part VI the role played by the organization in this regard.</i>		

Part V Type III Non-Functionally Integrated 509(a)(3) Supporting Organizations

- 1** Check here if the organization satisfied the Integral Part Test as a qualifying trust on Nov. 20, 1970 (explain in Part VI). **See instructions.** All other Type III non-functionally integrated supporting organizations must complete Sections A through E.

Section A - Adjusted Net Income		(A) Prior Year	(B) Current Year (optional)
1	Net short-term capital gain	1	
2	Recoveries of prior-year distributions	2	
3	Other gross income (see instructions)	3	
4	Add lines 1 through 3	4	
5	Depreciation and depletion	5	
6	Portion of operating expenses paid or incurred for production or collection of gross income or for management, conservation, or maintenance of property held for production of income (see instructions)	6	
7	Other expenses (see instructions)	7	
8	Adjusted Net Income (subtract lines 5, 6 and 7 from line 4)	8	
Section B - Minimum Asset Amount		(A) Prior Year	(B) Current Year (optional)
1	Aggregate fair market value of all non-exempt-use assets (see instructions for short tax year or assets held for part of year):	1	
a	Average monthly value of securities	1a	
b	Average monthly cash balances	1b	
c	Fair market value of other non-exempt-use assets	1c	
d	Total (add lines 1a, 1b, and 1c)	1d	
e	Discount claimed for blockage or other factors (explain in detail in Part VI):		
2	Acquisition indebtedness applicable to non-exempt use assets	2	
3	Subtract line 2 from line 1d	3	
4	Cash deemed held for exempt use. Enter 1-1/2% of line 3 (for greater amount, see instructions).	4	
5	Net value of non-exempt-use assets (subtract line 4 from line 3)	5	
6	Multiply line 5 by .035	6	
7	Recoveries of prior-year distributions	7	
8	Minimum Asset Amount (add line 7 to line 6)	8	
Section C - Distributable Amount			Current Year
1	Adjusted net income for prior year (from Section A, line 8, Column A)	1	
2	Enter 85% of line 1	2	
3	Minimum asset amount for prior year (from Section B, line 8, Column A)	3	
4	Enter greater of line 2 or line 3	4	
5	Income tax imposed in prior year	5	
6	Distributable Amount. Subtract line 5 from line 4, unless subject to emergency temporary reduction (see instructions)	6	
7	<input type="checkbox"/> Check here if the current year is the organization's first as a non-functionally-integrated Type III supporting organization (see instructions)		

Part V Type III Non-Functionally Integrated 509(a)(3) Supporting Organizations (continued)

Section D - Distributions	Current Year
1 Amounts paid to supported organizations to accomplish exempt purposes	
2 Amounts paid to perform activity that directly furthers exempt purposes of supported organizations, in excess of income from activity	
3 Administrative expenses paid to accomplish exempt purposes of supported organizations	
4 Amounts paid to acquire exempt-use assets	
5 Qualified set-aside amounts (prior IRS approval required)	
6 Other distributions (describe in Part VI). See instructions	
7 Total annual distributions. Add lines 1 through 6.	
8 Distributions to attentive supported organizations to which the organization is responsive (provide details in Part VI). See instructions	
9 Distributable amount for 2019 from Section C, line 6	
10 Line 8 amount divided by Line 9 amount	

Section E - Distribution Allocations (see instructions)	(i) Excess Distributions	(ii) Underdistributions Pre-2019	(iii) Distributable Amount for 2019
1 Distributable amount for 2019 from Section C, line 6			
2 Underdistributions, if any, for years prior to 2019 (reasonable cause required-- explain in Part VI). See instructions.			
3 Excess distributions carryover, if any, to 2019:			
a From 2014.			
b From 2015.			
c From 2016.			
d From 2017.			
e From 2018.			
f Total of lines 3a through e			
g Applied to underdistributions of prior years			
h Applied to 2019 distributable amount			
i Carryover from 2014 not applied (see instructions)			
j Remainder. Subtract lines 3g, 3h, and 3i from 3f.			
4 Distributions for 2019 from Section D, line 7:			
\$			
a Applied to underdistributions of prior years			
b Applied to 2019 distributable amount			
c Remainder. Subtract lines 4a and 4b from 4.			
5 Remaining underdistributions for years prior to 2019, if any. Subtract lines 3g and 4a from line 2. If the amount is greater than zero, explain in Part VI . See instructions.			
6 Remaining underdistributions for 2019. Subtract lines 3h and 4b from line 1. If the amount is greater than zero, explain in Part VI . See instructions.			
7 Excess distributions carryover to 2020. Add lines 3j and 4c.			
8 Breakdown of line 7:			
a Excess from 2015.			
b Excess from 2016.			
c Excess from 2017.			
d Excess from 2018.			
e Excess from 2019.			

Additional Data

Software ID:

Software Version:

EIN: 80-0631734

Name: NEW YORK GENOME CENTER INC

Part VI Supplemental Information. Provide the explanations required by Part II, line 10; Part II, line 17a or 17b; Part III, line 12; Part IV, Section A, lines 1, 2, 3b, 3c, 4b, 4c, 5a, 6, 9a, 9b, 9c, 11a, 11b, and 11c; Part IV, Section B, lines 1 and 2; Part IV, Section C, line 1; Part IV, Section D, lines 2 and 3; Part IV, Section E, lines 1c, 2a, 2b, 3a and 3b; Part V, line 1; Part V, Section B, line 1e; Part V Section D, lines 5, 6, and 8; and Part V, Section E, lines 2, 5, and 6. Also complete this part for any additional information. (See instructions).

Facts And Circumstances Test

SCHEDULE C
(Form 990 or 990-EZ)

Department of the Treasury
Internal Revenue Service

Political Campaign and Lobbying Activities
For Organizations Exempt From Income Tax Under section 501(c) and section 527

▶Complete if the organization is described below. ▶Attach to Form 990 or Form 990-EZ.
▶Go to www.irs.gov/Form990 for instructions and the latest information.

OMB No. 1545-0047

2019
Open to Public Inspection

If the organization answered "Yes" on Form 990, Part IV, Line 3, or Form 990-EZ, Part V, line 46 (Political Campaign Activities), then

- Section 501(c)(3) organizations: Complete Parts I-A and B. Do not complete Part I-C.
- Section 501(c) (other than section 501(c)(3)) organizations: Complete Parts I-A and C below. Do not complete Part I-B.
- Section 527 organizations: Complete Part I-A only.

If the organization answered "Yes" on Form 990, Part IV, Line 4, or Form 990-EZ, Part VI, line 47 (Lobbying Activities), then

- Section 501(c)(3) organizations that have filed Form 5768 (election under section 501(h)): Complete Part II-A. Do not complete Part II-B.
- Section 501(c)(3) organizations that have NOT filed Form 5768 (election under section 501(h)): Complete Part II-B. Do not complete Part II-A.

If the organization answered "Yes" on Form 990, Part IV, Line 5 (Proxy Tax) (see separate instructions) or Form 990-EZ, Part V, line 35c (Proxy Tax) (see separate instructions), then

- Section 501(c)(4), (5), or (6) organizations: Complete Part III.

Name of the organization NEW YORK GENOME CENTER INC	Employer identification number 80-0631734
--	--

Part I-A Complete if the organization is exempt under section 501(c) or is a section 527 organization.

1 Provide a description of the organization's direct and indirect political campaign activities in Part IV (see instructions for definition of "political campaign activities")

2 Political campaign activity expenditures (see instructions) ▶ \$ _____

3 Volunteer hours for political campaign activities (see instructions)

Part I-B Complete if the organization is exempt under section 501(c)(3).

1 Enter the amount of any excise tax incurred by the organization under section 4955 ▶ \$ _____

2 Enter the amount of any excise tax incurred by organization managers under section 4955 ▶ \$ _____

3 If the organization incurred a section 4955 tax, did it file Form 4720 for this year? Yes No

4a Was a correction made? Yes No

b If "Yes," describe in Part IV.

Part I-C Complete if the organization is exempt under section 501(c), except section 501(c)(3).

1 Enter the amount directly expended by the filing organization for section 527 exempt function activities ▶ \$ _____

2 Enter the amount of the filing organization's funds contributed to other organizations for section 527 exempt function activities ▶ \$ _____

3 Total exempt function expenditures. Add lines 1 and 2. Enter here and on Form 1120-POL, line 17b..... ▶ \$ _____

4 Did the filing organization file **Form 1120-POL** for this year? Yes No

5 Enter the names, addresses and employer identification number (EIN) of all section 527 political organizations to which the filing organization made payments. For each organization listed, enter the amount paid from the filing organization's funds. Also enter the amount of political contributions received that were promptly and directly delivered to a separate political organization, such as a separate segregated fund or a political action committee (PAC). If additional space is needed, provide information in Part IV.

(a) Name	(b) Address	(c) EIN	(d) Amount paid from filing organization's funds. If none, enter -0-.	(e) Amount of political contributions received and promptly and directly delivered to a separate political organization. If none, enter -0-.
1				
2				
3				
4				
5				
6				

Part II-B Complete if the organization is exempt under section 501(c)(3) and has NOT filed Form 5768 (election under section 501(h)).

For each "Yes" response on lines 1a through 1i below, provide in Part IV a detailed description of the lobbying activity.

		(a)		(b)
		Yes	No	Amount
1	During the year, did the filing organization attempt to influence foreign, national, state or local legislation, including any attempt to influence public opinion on a legislative matter or referendum, through the use of:			
a	Volunteers?		No	
b	Paid staff or management (include compensation in expenses reported on lines 1c through 1i)?	Yes		
c	Media advertisements?		No	
d	Mailings to members, legislators, or the public?		No	
e	Publications, or published or broadcast statements?		No	
f	Grants to other organizations for lobbying purposes?		No	
g	Direct contact with legislators, their staffs, government officials, or a legislative body?	Yes		2,125
h	Rallies, demonstrations, seminars, conventions, speeches, lectures, or any similar means?		No	
i	Other activities?	Yes		48,314
j	Total. Add lines 1c through 1i			50,439
2a	Did the activities in line 1 cause the organization to be not described in section 501(c)(3)?		No	
b	If "Yes," enter the amount of any tax incurred under section 4912			
c	If "Yes," enter the amount of any tax incurred by organization managers under section 4912			
d	If the filing organization incurred a section 4912 tax, did it file Form 4720 for this year?			

Part III-A Complete if the organization is exempt under section 501(c)(4), section 501(c)(5), or section 501(c)(6).

	Yes	No
1 Were substantially all (90% or more) dues received nondeductible by members?	1	
2 Did the organization make only in-house lobbying expenditures of \$2,000 or less?	2	
3 Did the organization agree to carry over lobbying and political expenditures from the prior year?	3	

Part III-B Complete if the organization is exempt under section 501(c)(4), section 501(c)(5), or section 501(c)(6) and if either (a) BOTH Part III-A, lines 1 and 2, are answered "No" OR (b) Part III-A, line 3, is answered "Yes."

1 Dues, assessments and similar amounts from members	1	
2 Section 162(e) nondeductible lobbying and political expenditures (do not include amounts of political expenses for which the section 527(f) tax was paid).		
a Current year	2a	
b Carryover from last year	2b	
c Total	2c	
3 Aggregate amount reported in section 6033(e)(1)(A) notices of nondeductible section 162(e) dues .	3	
4 If notices were sent and the amount on line 2c exceeds the amount on line 3, what portion of the excess does the organization agree to carryover to the reasonable estimate of nondeductible lobbying and political expenditure next year?	4	
5 Taxable amount of lobbying and political expenditures (see instructions)	5	

Part IV Supplemental Information

Provide the descriptions required for Part I-A, line 1; Part I-B, line 4; Part I-C, line 5; Part II-A (affiliated group list); Part II-A, lines 1 and 2 (see instructions), and Part II-B, line 1. Also, complete this part for any additional information.

Return Reference	Explanation
LOBBYING ACTIVITIES	SCHEDULE C, PART II-B, LINES 1G & 1I THROUGH ITS LEGISLATIVE CONSULTANTS, NYGC ADVOCATES AT THE STATE AND LOCAL LEVEL FOR GOVERNMENT FUNDS TO SUPPORT CURRENT OPERATIONS AND/OR EXPAND RESEARCH OPPORTUNITIES AT NYGC. NYGC ALSO MAINTAINS MEMBERSHIPS IN SEVERAL IRC SECTION 501(C)(6) ORGANIZATIONS THAT REPRESENT THE INTERESTS OF THE MEDICAL RESEARCH COMMUNITY; \$3,064 OF THE DUES THAT NYGC PAID TO THESE ASSOCIATIONS WERE ATTRIBUTABLE TO LOBBYING IN 2019. ADDITIONALLY, NYGC STAFF MAY, FROM TIME TO TIME, CONTACT FEDERAL LEGISLATORS OR THEIR STAFF TO ENCOURAGE THEIR SUPPORT FOR MATTERS OF CONCERN TO THE ACADEMIC MEDICAL RESEARCH COMMUNITY. SUCH CONTACT MAY INCLUDE WRITING LETTERS OR OCCASIONAL MEETINGS WITH PUBLIC OFFICIALS. THE APPROXIMATE COST ASSOCIATED WITH NYGC'S COMMUNICATIONS WITH THE FEDERAL GOVERNMENT IN 2019 IS \$2,125.

SCHEDULE D
(Form 990)

Department of the Treasury
Internal Revenue Service

Supplemental Financial Statements

OMB No. 1545-0047
2019
Open to Public Inspection

▶ Complete if the organization answered "Yes," on Form 990, Part IV, line 6, 7, 8, 9, 10, 11a, 11b, 11c, 11d, 11e, 11f, 12a, or 12b.
▶ Attach to Form 990.
▶ Go to www.irs.gov/Form990 for instructions and the latest information.

Name of the organization
NEW YORK GENOME CENTER INC

Employer identification number
80-0631734

Part I Organizations Maintaining Donor Advised Funds or Other Similar Funds or Accounts.
Complete if the organization answered "Yes" on Form 990, Part IV, line 6.

	(a) Donor advised funds	(b) Funds and other accounts
1 Total number at end of year		
2 Aggregate value of contributions to (during year)		
3 Aggregate value of grants from (during year)		
4 Aggregate value at end of year		

5 Did the organization inform all donors and donor advisors in writing that the assets held in donor advised funds are the organization's property, subject to the organization's exclusive legal control? Yes No

6 Did the organization inform all grantees, donors, and donor advisors in writing that grant funds can be used only for charitable purposes and not for the benefit of the donor or donor advisor, or for any other purpose conferring impermissible private benefit? Yes No

Part II Conservation Easements.
Complete if the organization answered "Yes" on Form 990, Part IV, line 7.

1 Purpose(s) of conservation easements held by the organization (check all that apply).

Preservation of land for public use (e.g., recreation or education) Preservation of an historically important land area

Protection of natural habitat Preservation of a certified historic structure

Preservation of open space

2 Complete lines 2a through 2d if the organization held a qualified conservation contribution in the form of a conservation easement on the last day of the tax year.

	Held at the End of the Year
a Total number of conservation easements	2a
b Total acreage restricted by conservation easements	2b
c Number of conservation easements on a certified historic structure included in (a)	2c
d Number of conservation easements included in (c) acquired after 7/25/06, and not on a historic structure listed in the National Register	2d

3 Number of conservation easements modified, transferred, released, extinguished, or terminated by the organization during the tax year ▶ _____

4 Number of states where property subject to conservation easement is located ▶ _____

5 Does the organization have a written policy regarding the periodic monitoring, inspection, handling of violations, and enforcement of the conservation easements it holds? Yes No

6 Staff and volunteer hours devoted to monitoring, inspecting, handling of violations, and enforcing conservation easements during the year ▶ _____

7 Amount of expenses incurred in monitoring, inspecting, handling of violations, and enforcing conservation easements during the year ▶ \$ _____

8 Does each conservation easement reported on line 2(d) above satisfy the requirements of section 170(h)(4)(B)(i) and section 170(h)(4)(B)(ii)? Yes No

9 In Part XIII, describe how the organization reports conservation easements in its revenue and expense statement, and balance sheet, and include, if applicable, the text of the footnote to the organization's financial statements that describes the organization's accounting for conservation easements.

Part III Organizations Maintaining Collections of Art, Historical Treasures, or Other Similar Assets.
Complete if the organization answered "Yes" on Form 990, Part IV, line 8.

1a If the organization elected, as permitted under SFAS 116 (ASC 958), not to report in its revenue statement and balance sheet works of art, historical treasures, or other similar assets held for public exhibition, education, or research in furtherance of public service, provide, in Part XIII, the text of the footnote to its financial statements that describes these items.

b If the organization elected, as permitted under SFAS 116 (ASC 958), to report in its revenue statement and balance sheet works of art, historical treasures, or other similar assets held for public exhibition, education, or research in furtherance of public service, provide the following amounts relating to these items:

(i) Revenue included on Form 990, Part VIII, line 1 ▶ \$ _____

(ii) Assets included in Form 990, Part X ▶ \$ _____

2 If the organization received or held works of art, historical treasures, or other similar assets for financial gain, provide the following amounts required to be reported under SFAS 116 (ASC 958) relating to these items:

a Revenue included on Form 990, Part VIII, line 1 ▶ \$ _____

b Assets included in Form 990, Part X ▶ \$ _____

Part III Organizations Maintaining Collections of Art, Historical Treasures, or Other Similar Assets (continued)

- 3** Using the organization's acquisition, accession, and other records, check any of the following that are a significant use of its collection items (check all that apply):
- a** Public exhibition
 - b** Scholarly research
 - c** Preservation for future generations
 - d** Loan or exchange programs
 - e** Other
- 4** Provide a description of the organization's collections and explain how they further the organization's exempt purpose in Part XIII.
- 5** During the year, did the organization solicit or receive donations of art, historical treasures or other similar assets to be sold to raise funds rather than to be maintained as part of the organization's collection? . . . **Yes** **No**

Part IV Escrow and Custodial Arrangements.

Complete if the organization answered "Yes" on Form 990, Part IV, line 9, or reported an amount on Form 990, Part X, line 21.

- 1a** Is the organization an agent, trustee, custodian or other intermediary for contributions or other assets not included on Form 990, Part X? **Yes** **No**
- b** If "Yes," explain the arrangement in Part XIII and complete the following table:
- | | Amount |
|---|--------|
| 1c Beginning balance | |
| 1d Additions during the year | |
| 1e Distributions during the year | |
| 1f Ending balance | |
- 2a** Did the organization include an amount on Form 990, Part X, line 21, for escrow or custodial account liability? . . . **Yes** **No**
- b** If "Yes," explain the arrangement in Part XIII. Check here if the explanation has been provided in Part XIII

Part V Endowment Funds.

Complete if the organization answered "Yes" on Form 990, Part IV, line 10.

	(a) Current year	(b) Prior year	(c) Two years back	(d) Three years back	(e) Four years back
1a Beginning of year balance					
b Contributions					
c Net investment earnings, gains, and losses					
d Grants or scholarships					
e Other expenditures for facilities and programs					
f Administrative expenses					
g End of year balance					

- 2** Provide the estimated percentage of the current year end balance (line 1g, column (a)) held as:
- a** Board designated or quasi-endowment ▶
 - b** Permanent endowment ▶
 - c** Temporarily restricted endowment ▶
- The percentages on lines 2a, 2b, and 2c should equal 100%.
- 3a** Are there endowment funds not in the possession of the organization that are held and administered for the organization by:
- | | | |
|--|---------------|-----------|
| | Yes | No |
| (i) unrelated organizations | 3a(i) | |
| (ii) related organizations | 3a(ii) | |
| b If "Yes" on 3a(ii), are the related organizations listed as required on Schedule R? | 3b | |
- 4** Describe in Part XIII the intended uses of the organization's endowment funds.

Part VI Land, Buildings, and Equipment.

Complete if the organization answered "Yes" on Form 990, Part IV, line 11a. See Form 990, Part X, line 10.

Description of property	(a) Cost or other basis (investment)	(b) Cost or other basis (other)	(c) Accumulated depreciation	(d) Book value
1a Land				
b Buildings				
c Leasehold improvements		70,852,332	18,936,299	51,916,033
d Equipment		30,652,288	28,251,470	2,400,818
e Other		28,404,370	25,049,820	3,354,550
Total. Add lines 1a through 1e. (Column (d) must equal Form 990, Part X, column (B), line 10(c).) . . . ▶				57,671,401

Part VII Investments—Other Securities.

Complete if the organization answered "Yes" on Form 990, Part IV, line 11b. See Form 990, Part X, line 12.

(a) Description of security or category (including name of security)	(b) Book value	(c) Method of valuation: Cost or end-of-year market value
(1) Financial derivatives		
(2) Closely-held equity interests		
(3) Other _____		
(A)		
(B)		
(C)		
(D)		
(E)		
(F)		
(G)		
(H)		
Total. (Column (b) must equal Form 990, Part X, col. (B) line 12.)		

Part VIII Investments—Program Related.

Complete if the organization answered 'Yes' on Form 990, Part IV, line 11c. See Form 990, Part X, line 13.

(a) Description of investment	(b) Book value	(c) Method of valuation: Cost or end-of-year market value
(1)		
(2)		
(3)		
(4)		
(5)		
(6)		
(7)		
(8)		
(9)		
Total. (Column (b) must equal Form 990, Part X, col.(B) line 13.)		

Part IX Other Assets.

Complete if the organization answered 'Yes' on Form 990, Part IV, line 11d. See Form 990, Part X, line 15.

(a) Description	(b) Book value
(1) SECURITY DEPOSITS	9,172,240
(2) DEFERRED COMPENSATION	370,154
(3)	
(4)	
(5)	
(6)	
(7)	
(8)	
(9)	
Total. (Column (b) must equal Form 990, Part X, col.(B) line 15.)	9,542,394

Part X Other Liabilities.

Complete if the organization answered 'Yes' on Form 990, Part IV, line 11e or 11f. See Form 990, Part X, line 25.

1. (a) Description of liability	(b) Book value
(1) Federal income taxes	0
(3)	
(4)	
(5)	
(6)	
(7)	
(8)	
(9)	
Total. (Column (b) must equal Form 990, Part X, col.(B) line 25.)	25,967,856

2. Liability for uncertain tax positions. In Part XIII, provide the text of the footnote to the organization's financial statements that reports the organization's liability for uncertain tax positions under FIN 48 (ASC 740). Check here if the text of the footnote has been provided in Part XIII

Part XI Reconciliation of Revenue per Audited Financial Statements With Revenue per Return.

Complete if the organization answered 'Yes' on Form 990, Part IV, line 12a.

1	Total revenue, gains, and other support per audited financial statements		1	45,525,304
2	Amounts included on line 1 but not on Form 990, Part VIII, line 12:			
a	Net unrealized gains (losses) on investments	2a		
b	Donated services and use of facilities	2b		
c	Recoveries of prior year grants	2c		
d	Other (Describe in Part XIII.)	2d		
e	Add lines 2a through 2d		2e	
3	Subtract line 2e from line 1		3	45,525,304
4	Amounts included on Form 990, Part VIII, line 12, but not on line 1:			
a	Investment expenses not included on Form 990, Part VIII, line 7b	4a		
b	Other (Describe in Part XIII.)	4b	-3,280,859	
c	Add lines 4a and 4b		4c	-3,280,859
5	Total revenue. Add lines 3 and 4c . (This must equal Form 990, Part I, line 12.)		5	42,244,445

Part XII Reconciliation of Expenses per Audited Financial Statements With Expenses per Return.

Complete if the organization answered 'Yes' on Form 990, Part IV, line 12a.

1	Total expenses and losses per audited financial statements		1	83,480,627
2	Amounts included on line 1 but not on Form 990, Part IX, line 25:			
a	Donated services and use of facilities	2a		
b	Prior year adjustments	2b		
c	Other losses	2c		
d	Other (Describe in Part XIII.)	2d	3,280,859	
e	Add lines 2a through 2d		2e	3,280,859
3	Subtract line 2e from line 1		3	80,199,768
4	Amounts included on Form 990, Part IX, line 25, but not on line 1:			
a	Investment expenses not included on Form 990, Part VIII, line 7b	4a		
b	Other (Describe in Part XIII.)	4b		
c	Add lines 4a and 4b		4c	
5	Total expenses. Add lines 3 and 4c . (This must equal Form 990, Part I, line 18.)		5	80,199,768

Part XIII Supplemental Information

Provide the descriptions required for Part II, lines 3, 5, and 9; Part III, lines 1a and 4; Part IV, lines 1b and 2b; Part V, line 4; Part X, line 2; Part XI, lines 2d and 4b; and Part XII, lines 2d and 4b. Also complete this part to provide any additional information.

Return Reference	Explanation
See Additional Data Table	

Additional Data

Software ID:

Software Version:

EIN: 80-0631734

Name: NEW YORK GENOME CENTER INC

Supplemental Information

Return Reference	Explanation
INCOME TAXES	SCHEDULE D, PART X, LINE 2 NYGC IS SUBJECT TO THE PROVISIONS OF THE FASB ASC SECTION 740-10-05, INCOME TAXES - OVERALL, RELATING TO ACCOUNTING AND REPORTING FOR UNCERTAINTY IN INCOME TAXES. NYGC RECOGNIZES THE EFFECT OF INCOME TAX POSITIONS ONLY IF THOSE POSITIONS ARE MORE LIKELY THAN NOT OF BEING SUSTAINED AND HAS DETERMINED IT DID NOT HAVE ANY EXPOSURE TO UNCERTAIN TAX POSITIONS DURING 2019 AND 2018.

Supplemental Information

Return Reference	Explanation
REVENUE AND EXPENSE RECONCILIATION	SCHEDULE D, PART XI, LINE 4B AND PART XII, LINE 2D (\$3,280,859) - RENTAL EXPENSES ALLOCABLE TO 990, PART VIII

**SCHEDULE F
(Form 990)**

Department of the Treasury
Internal Revenue Service

Statement of Activities Outside the United States

▶ Complete if the organization answered "Yes" to Form 990, Part IV, line 14b, 15, or 16.
▶ Attach to Form 990.
▶ Go to www.irs.gov/Form990 for instructions and the latest information.

OMB No. 1545-0047

2019

Open to Public Inspection

Name of the organization
NEW YORK GENOME CENTER INC

Employer identification number
80-0631734

Part I **General Information on Activities Outside the United States.** Complete if the organization answered "Yes" on Form 990, Part IV, line 14b.

- 1 For grantmakers.** Does the organization maintain records to substantiate the amount of its grants and other assistance, the grantees' eligibility for the grants or assistance, and the selection criteria used to award the grants or assistance? Yes No
- 2 For grantmakers.** Describe in Part V the organization's procedures for monitoring the use of its grants and other assistance outside the United States.
- 3** Activities per Region. (The following Part I, line 3 table can be duplicated if additional space is needed.)

(a) Region	(b) Number of offices in the region	(c) Number of employees, agents, and independent contractors in the region	(d) Activities conducted in region (by type) (such as, fundraising, program services, investments, grants to recipients located in the region)	(e) If activity listed in (d) is a program service, describe specific type of service(s) in the region	(f) Total expenditures for and investments in the region
See Add'l Data					
3a Sub-total	0	11			298,617
b Total from continuation sheets to Part I					
c Totals (add lines 3a and 3b)	0	11			298,617

Part II Grants and Other Assistance to Organizations or Entities Outside the United States. Complete if the organization answered "Yes" on Form 990, Part IV, line 15, for any recipient who received more than \$5,000. Part II can be duplicated if additional space is needed.

1 (a) Name of organization	(b) IRS code section and EIN (if applicable)	(c) Region	(d) Purpose of grant	(e) Amount of cash grant	(f) Manner of cash disbursement	(g) Amount of noncash assistance	(h) Description of noncash assistance	(i) Method of valuation (book, FMV, appraisal, other)
		Europe (Including Iceland and Greenland)	research subaward	37,301	WIRE			
		Europe (Including Iceland and Greenland)	RESEARCH	100,000	WIRE			

- 2 Enter total number of recipient organizations listed above that are recognized as charities by the foreign country, recognized as tax-exempt by the IRS, or for which the grantee or counsel has provided a section 501(c)(3) equivalency letter **2**
- 3 Enter total number of other organizations or entities **2**

Part IV Foreign Forms

- 1 Was the organization a U.S. transferor of property to a foreign corporation during the tax year? *If "Yes," the organization may be required to file Form 926, Return by a U.S. Transferor of Property to a Foreign Corporation (see Instructions for Form 926)* Yes No
- 2 Did the organization have an interest in a foreign trust during the tax year? *If "Yes," the organization may be required to separately file Form 3520, Annual Return to Report Transactions with Foreign Trusts and Receipt of Certain Foreign Gifts, and/or Form 3520-A, Annual Information Return of Foreign Trust With a U.S. Owner (see Instructions for Forms 3520 and 3520-A; don't file with Form 990)* Yes No
- 3 Did the organization have an ownership interest in a foreign corporation during the tax year? *If "Yes," the organization may be required to file Form 5471, Information Return of U.S. Persons with Respect to Certain Foreign Corporations. (see Instructions for Form 5471)* Yes No
- 4 Was the organization a direct or indirect shareholder of a passive foreign investment company or a qualified electing fund during the tax year? *If "Yes," the organization may be required to file Form 8621, Information Return by a Shareholder of a Passive Foreign Investment Company or Qualified Electing Fund. (see Instructions for Form 8621)* . Yes No
- 5 Did the organization have an ownership interest in a foreign partnership during the tax year? *If "Yes," the organization may be required to file Form 8865, Return of U.S. Persons with Respect to Certain Foreign Partnerships (see Instructions for Form 8865)* Yes No
- 6 Did the organization have any operations in or related to any boycotting countries during the tax year? *If "Yes," the organization may be required to separately file Form 5713, International Boycott Report (see Instructions for Form 5713; don't file with Form 990).* Yes No

Part V Supplemental Information

Provide the information required by Part I, line 2 (monitoring of funds); Part I, line 3, column (f) (accounting method; amounts of investments vs. expenditures per region); Part II, line 1 (accounting method); Part III (accounting method); and Part III, column (c) (estimated number of recipients), as applicable. Also complete this part to provide any additional information. See instructions.

990 Schedule F, Supplemental Information

Return Reference	Explanation
accounting method	<p>SCHEDULE F, PART I, LINE 3 THE PROGRAM EXPENDITURES ARE REPORTED ON THE ACCRUAL METHOD. MONITORING USE OF GRANT FUNDS SCHEDULE F, PART I, LINE 2 NYGC MONITORS SUBRECIPIENTS' USE OF GRANT FUNDS IN BOTH THE PREAWARD AND POST-AWARD STAGES IN COMPLIANCE WITH 2 CFR.200 (UNIFORM GUIDANCE). THIS REVIEW INCLUDES CONDUCTING APPROPRIATE CHECKS FOR SUSPENSION AND DEBARMENT. A SUBRECIPIENT MONITORING FORM IS SENT TO ALL SUB-AWARDEES AND THIS FORM IS THE BASIS BY WHICH NYGC ASSESSES RISK. IN THE POST-AWARD PHASE, NYGC MONITORS PROGRAMMATIC PROGRESS IN A MANNER CONSISTENT WITH THE TERMS AND CONDITIONS OF THE AWARD. NYGC REVIEWS ANY SUBRECIPIENT EXPENSES INVOICED TO NYGC FOR ALLOWABILITY WITH REGARD TO RELEVANT COST PRINCIPLES AND BUDGETARY RESTRICTIONS BEFORE PAYMENT. SUBAWARDS ELIGIBLE FOR FFATA REPORTING ARE RECORDED IN THE FSRs (THE FFATA SUBAWARD REPORTING SYSTEM) IN ACCORDANCE WITH THE FEDERAL REPORTING REQUIREMENTS FOR FIRST TIER SUBAWARDS UNDER NYGC'S PRIME FEDERAL AWARDS.</p>

Additional Data

Software ID:

Software Version:

EIN: 80-0631734

Name: NEW YORK GENOME CENTER INC

Form 990 Schedule F Part I - Activities Outside The United States

(a) Region	(b) Number of offices in the region	(c) Number of employees or agents in region	(d) Activities conducted in region (by type) (i.e., fundraising, program services, grants to recipients located in the region)	(e) If activity listed in (d) is a program service, describe specific type of service(s) in region	(f) Total expenditures for region
Europe (Including Iceland and Greenland)	0	8	Program Services	RESEARCH	155,453
North America	0	3	Program Services	RESEARCH	5,863

Form 990 Schedule F Part I - Activities Outside The United States

(a) Region	(b) Number of offices in the region	(c) Number of employees or agents in region	(d) Activities conducted in region (by type) (i.e., fundraising, program services, grants to recipients located in the region)	(e) If activity listed in (d) is a program service, describe specific type of service(s) in region	(f) Total expenditures for region
Europe (Including Iceland and Greenland)			Program Services	COLLABORATION	137,301

SCHEDULE G
(Form 990 or 990-EZ)

Department of the Treasury
Internal Revenue Service

**Supplemental Information Regarding
Fundraising or Gaming Activities**

Complete if the organization answered "Yes" on Form 990, Part IV, lines 17, 18, or 19, or if the organization entered more than \$15,000 on Form 990-EZ, line 6a.
▶ Attach to Form 990 or Form 990-EZ.
▶ Go to www.irs.gov/Form990 for instructions and the latest information.

OMB No. 1545-0047

2019

Open to Public Inspection

Name of the organization
NEW YORK GENOME CENTER INC

Employer identification number
80-0631734

Part I Fundraising Activities. Complete if the organization answered "Yes" on Form 990, Part IV, line 17. Form 990-EZ filers are not required to complete this part.

- 1** Indicate whether the organization raised funds through any of the following activities. Check all that apply.
- a** Mail solicitations
 - b** Internet and email solicitations
 - c** Phone solicitations
 - d** In-person solicitations
 - e** Solicitation of non-government grants
 - f** Solicitation of government grants
 - g** Special fundraising events
- 2a** Did the organization have a written or oral agreement with any individual (including officers, directors, trustees or key employees listed in Form 990, Part VII) or entity in connection with professional fundraising services? Yes No
- b** If "Yes," list the 10 highest paid individuals or entities (fundraisers) pursuant to agreements under which the fundraiser is to be compensated at least \$5,000 by the organization.

(i) Name and address of individual or entity (fundraiser)	(ii) Activity	(iii) Did fundraiser have custody or control of contributions?		(iv) Gross receipts from activity	(v) Amount paid to (or retained by) fundraiser listed in col. (i)	(vi) Amount paid to (or retained by) organization
		Yes	No			
COMMUNITY COUNSELLING SERVICE	CAMPAIGN SERVICES		No		120,056	-120,056
Total					120,056	-120,056

- 3** List all states in which the organization is registered or licensed to solicit contributions or has been notified it is exempt from registration or licensing.

AL, AK, AR, CA, CO, CT, FL, GA, HI, IL, KS, KY, LA, ME, MD, MA, MI, MS, MO, MT, NH, NJ, NM, NY, NC, ND, OH, OK, OR, PA, RI, SC, TN, UT, VA, WA, WV, WI

Part II Fundraising Events. Complete if the organization answered "Yes" on Form 990, Part IV, line 18, or reported more than \$15,000 of fundraising event contributions and gross income on Form 990-EZ, lines 1 and 6b. List events with gross receipts greater than \$5,000.

Revenue		(a) Event #1	(b) Event #2	(c) Other events	(d) Total events
		(event type)	(event type)	(total number)	(add col. (a) through col. (c))
Revenue	1 Gross receipts				
	2 Less: Contributions				
	3 Gross income (line 1 minus line 2)				
Direct Expenses	4 Cash prizes				
	5 Noncash prizes				
	6 Rent/facility costs				
	7 Food and beverages				
	8 Entertainment				
	9 Other direct expenses				
	10 Direct expense summary. Add lines 4 through 9 in column (d) ▶				
11 Net income summary. Subtract line 10 from line 3, column (d) ▶					

Part III Gaming. Complete if the organization answered "Yes" on Form 990, Part IV, line 19, or reported more than \$15,000 on Form 990-EZ, line 6a.

Revenue		(a) Bingo	(b) Pull tabs/Instant bingo/progressive bingo	(c) Other gaming	(d) Total gaming (add col.(a) through col.(c))
		1 Gross revenue			
Direct Expenses	2 Cash prizes				
	3 Noncash prizes				
	4 Rent/facility costs				
	5 Other direct expenses				
	6 Volunteer labor	<input type="checkbox"/> Yes _____ % <input type="checkbox"/> No	<input type="checkbox"/> Yes _____ % <input type="checkbox"/> No	<input type="checkbox"/> Yes _____ % <input type="checkbox"/> No	
7 Direct expense summary. Add lines 2 through 5 in column (d) ▶					
8 Net gaming income summary. Subtract line 7 from line 1, column (d) ▶					

9 Enter the state(s) in which the organization conducts gaming activities: _____

a Is the organization licensed to conduct gaming activities in each of these states? Yes No

b If "No," explain: _____

10a Were any of the organization's gaming licenses revoked, suspended or terminated during the tax year? Yes No

b If "Yes," explain: _____

- 11** Does the organization conduct gaming activities with nonmembers? Yes No
- 12** Is the organization a grantor, beneficiary or trustee of a trust or a member of a partnership or other entity formed to administer charitable gaming? Yes No
- 13** Indicate the percentage of gaming activity conducted in:
- | | | |
|--------------------------------------|------------|---|
| a The organization's facility | 13a | % |
| b An outside facility | 13b | % |
- 14** Enter the name and address of the person who prepares the organization's gaming/special events books and records:

Name ▶

Address ▶

- 15a** Does the organization have a contract with a third party from whom the organization receives gaming revenue? Yes No
- b** If "Yes," enter the amount of gaming revenue received by the organization ▶ \$ _____ and the amount of gaming revenue retained by the third party ▶ \$ _____.
- c** If "Yes," enter name and address of the third party:

Name ▶

Address ▶

16 Gaming manager information:

Name ▶

Gaming manager compensation ▶ \$

Description of services provided ▶

Director/officer

Employee

Independent contractor

17 Mandatory distributions:

- a** Is the organization required under state law to make charitable distributions from the gaming proceeds to retain the state gaming license? Yes No
- b** Enter the amount of distributions required under state law distributed to other exempt organizations or spent in the organization's own exempt activities during the tax year ▶ \$ _____

Part IV Supplemental Information. Provide the explanations required by Part I, line 2b, columns (iii) and (v); and Part III, lines 9, 9b, 10b, 15b, 15c, 16, and 17b, as applicable. Also provide any additional information. See instructions.

Return Reference	Explanation
Schedule G, Part I, Line 2b	COMMUNITY COUNSELLING SERVICE'S ADDRESS: 527 MADISON AVENUE 5TH FLOOR NEW YORK, NY 10022 SCHEDULE G, PART I, LINE 2B, COLUMN (IV) NYGC UTILIZES THE SERVICES OF A FUNDRAISING ADVISOR TO CONSULT ON THE DEVELOPMENT ACTIVITIES OF THE ORGANIZATION. THE ADVISOR OFFERS ADVICE ON STRATEGY AND IS NOT INVOLVED IN DIRECT FUNDRAISING. DUE TO THE NATURE OF THESE ARRANGEMENTS, NYGC IS UNABLE TO REASONABLY DETERMINE THE GROSS RECEIPTS FROM THE FUNDRAISING ACTIVITIES THAT ARE SOLELY ATTRIBUTABLE TO THIS ADVISOR.

Note: To capture the full content of this document, please select landscape mode (11" x 8.5") when printing.

Schedule I (Form 990)

Grants and Other Assistance to Organizations, Governments and Individuals in the United States

OMB No. 1545-0047

2019

Open to Public Inspection

Department of the Treasury Internal Revenue Service

Complete if the organization answered "Yes," on Form 990, Part IV, line 21 or 22.

Attach to Form 990.

Go to www.irs.gov/Form990 for the latest information.

Name of the organization NEW YORK GENOME CENTER INC

Employer identification number 80-0631734

Part I General Information on Grants and Assistance

- 1 Does the organization maintain records to substantiate the amount of the grants or assistance...
2 Describe in Part IV the organization's procedures for monitoring the use of grant funds in the United States.

Part II Grants and Other Assistance to Domestic Organizations and Domestic Governments. Complete if the organization answered "Yes" on Form 990, Part IV, line 21, for any recipient that received more than \$5,000.

Table with 8 columns: (a) Name and address of organization or government, (b) EIN, (c) IRC section (if applicable), (d) Amount of cash grant, (e) Amount of non-cash assistance, (f) Method of valuation (book, FMV, appraisal, other), (g) Description of noncash assistance, (h) Purpose of grant or assistance. Rows 1-12.

2 Enter total number of section 501(c)(3) and government organizations listed in the line 1 table.
3 Enter total number of other organizations listed in the line 1 table.

Part III Grants and Other Assistance to Domestic Individuals. Complete if the organization answered "Yes" on Form 990, Part IV, line 22.

Part III can be duplicated if additional space is needed.

(a) Type of grant or assistance	(b) Number of recipients	(c) Amount of cash grant	(d) Amount of noncash assistance	(e) Method of valuation (book, FMV, appraisal, other)	(f) Description of noncash assistance
(1)					
(2)					
(3)					
(4)					
(5)					
(6)					
(7)					

Part IV Supplemental Information. Provide the information required in Part I, line 2; Part III, column (b); and any other additional information.

Return Reference	Explanation
MONITORING USE OF GRANT FUNDS	SCHEDULE I, PART I, LINE 2 NYGC MONITORS SUBRECIPIENTS' USE OF GRANT FUNDS IN BOTH THE PREAWARD AND POST-AWARD STAGES IN COMPLIANCE WITH 2 CFR.200 (UNIFORM GUIDANCE). THIS REVIEW INCLUDES CONDUCTING APPROPRIATE CHECKS FOR SUSPENSION AND DEBARMENT. A SUBRECIPIENT MONITORING FORM IS SENT TO ALL SUB-AWARDEES AND THIS FORM IS THE BASIS BY WHICH NYGC ASSESSES RISK. IN THE POST-AWARD PHASE, NYGC MONITORS PROGRAMMATIC PROGRESS IN A MANNER CONSISTENT WITH THE TERMS AND CONDITIONS OF THE AWARD. NYGC REVIEWS ANY SUBRECIPIENT EXPENSES INVOICED TO NYGC FOR ALLOWABILITY WITH REGARD TO RELEVANT COST PRINCIPLES AND BUDGETARY RESTRICTIONS BEFORE PAYMENT. SUBAWARDS ELIGIBLE FOR FFATA REPORTING ARE RECORDED IN THE FSRs (THE FFATA SUBAWARD REPORTING SYSTEM) IN ACCORDANCE WITH THE FEDERAL REPORTING REQUIREMENTS FOR FIRST TIER SUBAWARDS UNDER NYGC'S PRIME FEDERAL AWARDS.

Additional Data

Software ID:
Software Version:
EIN: 80-0631734
Name: NEW YORK GENOME CENTER INC

Form 990, Schedule I, Part II, Grants and Other Assistance to Domestic Organizations and Domestic Governments.

(a) Name and address of organization or government	(b) EIN	(c) IRC section if applicable	(d) Amount of cash grant	(e) Amount of non-cash assistance	(f) Method of valuation (book, FMV, appraisal, other)	(g) Description of non-cash assistance	(h) Purpose of grant or assistance
TRUSTEES OF COLUMBIA UNIVERSITY CITY OF NY 630 W 168TH ST NEW YORK, NY 10032	13-5598093	501(C)(3)	323,877				RESEARCH SUBAWARD
COLD SPRING HARBOR LABORATORY 1 BUNGTOWN RD COLD SPRING HARBOR, NY 11724	11-2013303	501(C)(3)	501,045				RESEARCH SUBAWARD

Form 990, Schedule I, Part II, Grants and Other Assistance to Domestic Organizations and Domestic Governments.

(a) Name and address of organization or government	(b) EIN	(c) IRC section if applicable	(d) Amount of cash grant	(e) Amount of non-cash assistance	(f) Method of valuation (book, FMV, appraisal, other)	(g) Description of non-cash assistance	(h) Purpose of grant or assistance
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI ONE GUSTAVE L LEVY PL BOX 1075 NEW YORK, NY 10029	13-6171197	501(C)(3)	39,571				RESEARCH SUBAWARD
REGENTS OF THE UNIVERSITY OF CALIFORNIA-SF 1550 4TH STREET SAN FRANCISCO, CA 94158	94-6036493	CA	22,364				RESEARCH SUBAWARD

Form 990, Schedule I, Part II, Grants and Other Assistance to Domestic Organizations and Domestic Governments.

(a) Name and address of organization or government	(b) EIN	(c) IRC section if applicable	(d) Amount of cash grant	(e) Amount of non-cash assistance	(f) Method of valuation (book, FMV, appraisal, other)	(g) Description of non-cash assistance	(h) Purpose of grant or assistance
REGENTS OF THE UNIVERSITY OF CALIFORNIA-LA 11000 KINROSS AVE LOS ANGELES, CA 90095	95-6006143	CA	45,530				RESEARCH SUBAWARD
UNIVERSITY OF WASHINGTON 4333 BROOKLYN AVE NE SEATTLE, WA 98195	91-6001537	WA	225,498				RESEARCH SUBAWARD

Form 990, Schedule I, Part II, Grants and Other Assistance to Domestic Organizations and Domestic Governments.

(a) Name and address of organization or government	(b) EIN	(c) IRC section if applicable	(d) Amount of cash grant	(e) Amount of non-cash assistance	(f) Method of valuation (book, FMV, appraisal, other)	(g) Description of non-cash assistance	(h) Purpose of grant or assistance
THE ROCKEFELLER UNIVERSITY 1230 YORK AVENUE NEW YORK, NY 10064	13-1624158	501(C)(3)	271,894				RESEARCH SUBAWARD
Massachusetts General Hospital 55 Fruit Street Boston, MA 021142696	04-2697983	501(C)(3)	39,958				RESEARCH SUBAWARD

Form 990, Schedule I, Part II, Grants and Other Assistance to Domestic Organizations and Domestic Governments.

(a) Name and address of organization or government	(b) EIN	(c) IRC section if applicable	(d) Amount of cash grant	(e) Amount of non-cash assistance	(f) Method of valuation (book, FMV, appraisal, other)	(g) Description of non-cash assistance	(h) Purpose of grant or assistance
Johns Hopkins University 3400 N Charles St BALTIMORE, MD 21218	52-0595110	501(c)(3)	36,683				RESEARCH SUBAWARD
The Broad Institute Inc 415 Main St CAMBRIDGE, MA 02142	26-3428781	501(c)(3)	171,017				RESEARCH SUBAWARD

Form 990, Schedule I, Part II, Grants and Other Assistance to Domestic Organizations and Domestic Governments.

(a) Name and address of organization or government	(b) EIN	(c) IRC section if applicable	(d) Amount of cash grant	(e) Amount of non-cash assistance	(f) Method of valuation (book, FMV, appraisal, other)	(g) Description of non-cash assistance	(h) Purpose of grant or assistance
Weill Cornell Medical College 1300 York Ave New York, NY 10065	15-0532082	501(c)(3)	8,156				RESEARCH SUBAWARD

Schedule J
(Form 990)

Compensation Information

OMB No. 1545-0047

2019

Open to Public Inspection

For certain Officers, Directors, Trustees, Key Employees, and Highest Compensated Employees

▶ **Complete if the organization answered "Yes" on Form 990, Part IV, line 23.**

▶ **Attach to Form 990.**

▶ **Go to www.irs.gov/Form990 for instructions and the latest information.**

Department of the Treasury
Internal Revenue Service

Name of the organization
NEW YORK GENOME CENTER INC

Employer identification number
80-0631734

Part I Questions Regarding Compensation

	Yes	No
<p>1a Check the appropriate box(es) if the organization provided any of the following to or for a person listed on Form 990, Part VII, Section A, line 1a. Complete Part III to provide any relevant information regarding these items.</p> <p> <input type="checkbox"/> First-class or charter travel <input type="checkbox"/> Travel for companions <input checked="" type="checkbox"/> Tax idemnification and gross-up payments <input type="checkbox"/> Discretionary spending account </p> <p> <input checked="" type="checkbox"/> Housing allowance or residence for personal use <input type="checkbox"/> Payments for business use of personal residence <input type="checkbox"/> Health or social club dues or initiation fees <input type="checkbox"/> Personal services (e.g., maid, chauffeur, chef) </p>		
<p>b If any of the boxes on Line 1a are checked, did the organization follow a written policy regarding payment or reimbursement or provision of all of the expenses described above? If "No," complete Part III to explain</p>	1b Yes	
<p>2 Did the organization require substantiation prior to reimbursing or allowing expenses incurred by all directors, trustees, officers, including the CEO/Executive Director, regarding the items checked on Line 1a?</p>	2 Yes	
<p>3 Indicate which, if any, of the following the filing organization used to establish the compensation of the organization's CEO/Executive Director. Check all that apply. Do not check any boxes for methods used by a related organization to establish compensation of the CEO/Executive Director, but explain in Part III.</p> <p> <input type="checkbox"/> Compensation committee <input type="checkbox"/> Independent compensation consultant <input type="checkbox"/> Form 990 of other organizations </p> <p> <input type="checkbox"/> Written employment contract <input type="checkbox"/> Compensation survey or study <input checked="" type="checkbox"/> Approval by the board or compensation committee </p>		
<p>4 During the year, did any person listed on Form 990, Part VII, Section A, line 1a, with respect to the filing organization or a related organization:</p> <p>a Receive a severance payment or change-of-control payment?</p> <p>b Participate in, or receive payment from, a supplemental nonqualified retirement plan?</p> <p>c Participate in, or receive payment from, an equity-based compensation arrangement?</p> <p>If "Yes" to any of lines 4a-c, list the persons and provide the applicable amounts for each item in Part III.</p>	4a Yes	4b Yes
	4c	No
<p>Only 501(c)(3), 501(c)(4), and 501(c)(29) organizations must complete lines 5-9.</p> <p>5 For persons listed on Form 990, Part VII, Section A, line 1a, did the organization pay or accrue any compensation contingent on the revenues of:</p> <p>a The organization?</p> <p>b Any related organization?</p> <p>If "Yes," on line 5a or 5b, describe in Part III.</p>	5a	5b No
		No
<p>6 For persons listed on Form 990, Part VII, Section A, line 1a, did the organization pay or accrue any compensation contingent on the net earnings of:</p> <p>a The organization?</p> <p>b Any related organization?</p> <p>If "Yes," on line 6a or 6b, describe in Part III.</p>	6a	6b No
		No
<p>7 For persons listed on Form 990, Part VII, Section A, line 1a, did the organization provide any nonfixed payments not described in lines 5 and 6? If "Yes," describe in Part III.</p>	7 Yes	
<p>8 Were any amounts reported on Form 990, Part VII, paid or accrued pursuant to a contract that was subject to the initial contract exception described in Regulations section 53.4958-4(a)(3)? If "Yes," describe in Part III.</p>	8	No
<p>9 If "Yes" on line 8, did the organization also follow the rebuttable presumption procedure described in Regulations section 53.4958-6(c)?</p>	9	

Part III Supplemental Information

Provide the information, explanation, or descriptions required for Part I, lines 1a, 1b, 3, 4a, 4b, 4c, 5a, 5b, 6a, 6b, 7, and 8, and for Part II. Also complete this part for any additional information.

Return Reference	Explanation
SCHEDULE J, PART I, LINE 1	TAX INDEMNIFICATION AND GROSS-UP PAYMENTS NYGC PAYS TAXES ON BEHALF OF ITS PRESIDENT & CHIEF OPERATING OFFICER (COO) VIA A PAYROLL TAX GROSS UP FOR LIFE INSURANCE, DISABILITY AND LONG-TERM CARE BENEFITS PURSUANT TO HER OFFER LETTER. AN EXECUTIVE COMPENSATION COMMITTEE OF INDEPENDENT BOARD MEMBERS IS RESPONSIBLE FOR ESTABLISHING HER COMPENSATION PACKAGE, WHICH IS THEN APPROVED BY THE BOARD OF DIRECTORS. HOUSING ALLOWANCE OR RESIDENCE FOR PERSONAL USE NYGC PROVIDES A HOUSING ALLOWANCE TO THE SCIENTIFIC DIRECTOR & CHIEF EXECUTIVE OFFICER (CEO) AND PRESIDENT & COO. NYGC SELECTIVELY OFFERS HOUSING ALLOWANCES TO EMPLOYEES, PRINCIPALLY AS A RECRUITING TOOL FOR NEW FACULTY AND POSTDOCTORAL FELLOWS. SUBSIDIZED HOUSING OR HOUSING ALLOWANCES ARE COMMONLY OFFERED BY PEER ACADEMIC INSTITUTIONS IN NEW YORK CITY TO HELP FACULTY AND OTHER RESEARCHERS DEFRAY THE HIGH COST OF HOUSING. THE VALUE OF THIS ASSISTANCE IS TREATED AS TAXABLE COMPENSATION TO THE EMPLOYEE.
EXECUTIVE COMPENSATION	SCHEDULE J, PART I, LINE 3 IN 2019, NYGC'S SCIENTIFIC DIRECTOR & CEO WAS EMPLOYED BY AN UNRELATED ENTITY AND LEASED TO NYGC TO DEVOTE 80% OF HIS TIME AND EFFORT TO SERVING AS NYGC'S SCIENTIFIC DIRECTOR & CEO, AN OFFICER OF THE CORPORATION AND AS AN ASSOCIATE MEMBER OF NYGC'S FACULTY. HIS NYGC COMPENSATION IS 80% OF THE COMPENSATION THAT IS SET BY THE UNRELATED ENTITY. HE OVERSAW NYGC'S RESEARCH PROGRAM AND UNDERTOOK OTHER ACTIVITIES AS NYGC'S BOARD OF DIRECTORS REQUESTED FROM TIME TO TIME. THE SCIENTIFIC DIRECTOR & CEO DEVOTED 20% OF HIS TIME TO HIS DUTIES AT THE UNRELATED ENTITY, WHERE HE MAINTAINS A LABORATORY AND CONDUCTS INDEPENDENT, INVESTIGATOR-INITIATED RESEARCH PROJECTS. HIS COMPENSATION WAS ESTABLISHED BY THE UNRELATED ENTITY, WHO IS HIS EMPLOYER, AND IS NOT CONTROLLED BY NYGC. HOWEVER, IN LATE 2018, NYGC HIRED AN INDEPENDENT COMPENSATION CONSULTANT TO PERFORM AN EXECUTIVE TOTAL COMPENSATION STUDY OF SENIOR MANAGEMENT'S COMPENSATION, INCLUDING THE SCIENTIFIC DIRECTOR & CEO. RESULTS OF THIS STUDY WERE PROVIDED TO THE AD-HOC COMPENSATION COMMITTEE IN EARLY 2019 AND THE COMMITTEE DISCUSSED THEM. THE REVIEW SHOWED THAT THE COMPENSATION PAID TO ALL MEMBERS OF SENIOR MANAGEMENT, INCLUDING THE CEO, WAS REASONABLE. ON RECOMMENDATION OF THE AD-HOC COMMITTEE, THE BOARD OF DIRECTORS APPROVED A 5% MERIT INCREASE TO THE BASE SALARY OF THE SCIENTIFIC DIRECTOR & CEO FOR 2019. THIS APPROVAL WAS MEMORIALIZED IN THE BOARD MINUTES. WHILE THE SCIENTIFIC DIRECTOR & CEO'S COMPENSATION IS SET BY AN UNRELATED ENTITY, THE AD-HOC COMPENSATION COMMITTEE COMMUNICATED WITH THE UNRELATED ENTITY AND APPROVED HIS MERIT INCREASE IN 2019. THE SCIENTIFIC DIRECTOR & CEOS 5% MERIT INCREASE WAS BASED ON HIS FULL COMPENSATION AT THE UNRELATED ENTITY. HIS COMPENSATION AT NYGC IS 80% OF THE COMPENSATION THAT IS SET BY THE UNRELATED ENTITY. SEVERANCE PAYMENTS SCHEDULE J, PART I, LINE 4A TOBY BLOOM, FORMER KEY EMPLOYEE - MS. BLOOM'S COMPENSATION INCLUDES A SEVERANCE PAYMENT OF \$125,000.
SUPPLEMENTAL NONQUALIFIED RETIREMENT PLAN	SCHEDULE J, PART I, LINE 4B and Part II NYGC HAS A DEFERRED COMPENSATION PLAN FOR THE PRESIDENT & COO. IN 2019, \$200,000 WAS DEFERRED AND \$642,337.32, DEFERRED FROM PRIOR YEARS, WAS DISTRIBUTED. The distribution is reported as taxable income on Part II, column (B)(iii) and column (F). NON-FIXED PAYMENTS SCHEDULE J, PART I, LINE 7 THE FOLLOWING INDIVIDUALS RECEIVED DISCRETIONARY BONUSES IN 2019: SVP, GENOME TECHNOLOGIES, CHIEF OF STAFF, OFFICE OF SCIENTIFIC DIRECTOR AND CEO AND SENIOR DIRECTOR, SOFTWARE ENGINEERING.

Part IV Business Transactions Involving Interested Persons.

Complete if the organization answered "Yes" on Form 990, Part IV, line 28a, 28b, or 28c.

(a) Name of interested person	(b) Relationship between interested person and the organization	(c) Amount of transaction	(d) Description of transaction	(e) Sharing of organization's revenues?	
				Yes	No
(1) SILAS MANIATIS	FAMILY MEMBER	135,701	COMPENSATION		No

Part V Supplemental Information

Provide additional information for responses to questions on Schedule L (see instructions).

Return Reference	Explanation
------------------	-------------

SCHEDULE O
(Form 990 or 990-EZ)

Department of the Treasury

Internal Revenue Service
Name of the organization

NEW YORK GENOME CENTER INC

Supplemental Information to Form 990 or 990-EZ

Complete to provide information for responses to specific questions on Form 990 or 990-EZ or to provide any additional information.

▶ Attach to Form 990 or 990-EZ.

▶ Go to www.irs.gov/Form990 for the latest information.

OMB No. 1545-0047

2019

Open to Public Inspection

Employer identification number

80-0631734

990 Schedule O, Supplemental Information

Return Reference	Explanation
THE ORGANIZATIONS MISSION	<p>FORM 990, PART I, LINE 1 & PART III, LINE 1: NYGC IS ORGANIZED AND OPERATED AS AN INDEPENDENT, NON-PROFIT CORPORATION, DEDICATED TO STATE-OF-THE-ART, WORLD-CLASS GENOMIC RESEARCH, SEQUENCING AND BIOINFORMATICS, WHOSE MEMBERS INCLUDE LEADING ACADEMIC, MEDICAL AND RESEARCH INSTITUTIONS. IT CREATES AND USES ADVANCED GENOMICS TO UNDERSTAND THE GENETIC BASIS OF DISEASE. NYGC HAS THE FOLLOWING KEY OBJECTIVES: (I) FOSTERING INTELLECTUALLY VIBRANT RESEARCH COLLABORATIONS IN THE ACADEMIC AND SCIENTIFIC COMMUNITY IN NEW YORK CITY, ACROSS THE COUNTRY AND AROUND THE WORLD; (II) RECRUITING AND RETAINING WORLD-CLASS SCIENTIFIC TALENT TO LEAD THE SCIENTIFIC DEVELOPMENT OF THE ORGANIZATION; (III) SUPPORTING RESEARCH CONDUCTED BY THE INSTITUTIONAL FOUNDING MEMBERS, OTHER ACADEMIC, RESEARCH AND MEDICAL INSTITUTIONS, AND THE BIOTECHNOLOGY/PHARMACEUTICAL INDUSTRY TO ADVANCE NYGC'S SCIENTIFIC PROGRAM AND GENOMIC RESEARCH; (IV) DEVELOPING INNOVATIVE EXPERIMENTAL AND COMPUTATIONAL GENOMIC METHODS BASED UPON THE RESEARCH AND SEQUENCING ACTIVITIES CONDUCTED AT THE ORGANIZATION'S FACILITY, FOR THE BROADER BENEFIT OF THE RESEARCH COMMUNITY; (V) ADVANCING RESEARCH TO SUPPORT THE DEVELOPMENT OF NEW TREATMENTS, THERAPIES AND THERAPEUTICS TO TREAT HUMAN DISEASE; (VI) PROVIDING TRAINING TO THE ACADEMIC, RESEARCH AND TECHNOLOGY COMMUNITIES; AND (VII) CONDUCTING ACTIVITIES ANCILLARY TO THESE OBJECTIVES. FORM 990, PART III, LINE 4A (CONTINUED) IN 2019, NYGC SEQUENCED OVER 12,000 WHOLE GENOME SAMPLES, COMPLETED 490 PROJECTS, AND COLLABORATED WITH 131 INVESTIGATORS FROM 92 INSTITUTIONS WORLDWIDE. PROGRAM SERVICE ACCOMPLISHMENTS FORM 990, PART III, LINE 4A & LINE 4B: NYGC IS AN INDEPENDENT, NONPROFIT ACADEMIC RESEARCH INSTITUTION WITH THE MISSION OF ADVANCING CLINICAL CARE THROUGH TRANSFORMATIVE GENOMIC RESEARCH. NYGC'S WORK BUILDS ON THE EXPERTISE AND EXPERIENCE THAT NYGC HAS DEVELOPED SINCE ITS FOUNDING IN 2010 AND AUGMENTS RESEARCH BEING CONDUCTED BY NYGC MEMBER INSTITUTIONS. COLLABORATING WITH PREMIER ACADEMIC, MEDICAL AND INDUSTRY LEADERS ACROSS THE GLOBE, NYGC IS CONDUCTING DISEASE-BASED GENOMIC RESEARCH IN AREAS WHERE IT HAS DEVELOPED A STRONG AND SUCCESSFUL TRACK RECORD, PARTICULARLY IN NEURODEGENERATIVE DISEASES SUCH AS ALS, NEUROPSYCHIATRIC DISEASES, PRINCIPALLY IN AUTISM, AND CANCER, FOCUSING ON UNDERSERVED POPULATIONS AND RARE CANCERS, AMONG OTHERS. IN 2020, NYGC ALSO EXPANDED ITS EXPERTISE TO COVID-19 RESEARCH. THROUGH INNOVATIVE RESEARCH AND GENOMIC DISCOVERY, NYGC'S GOAL IS TO ADVANCE HUMAN HEALTH. NYGC, ITS MEMBER INSTITUTIONS AND PARTNERS ARE UNITED IN THIS UNPRECEDENTED COLLABORATION OF TECHNOLOGY, SCIENCE AND MEDICINE, DESIGNED TO HARNESS THE POWER OF INNOVATION AND GENOMICS TO MAKE GROUNDBREAKING NEW DISCOVERIES IN THESE DISEASES. THEIR SHARED OBJECTIVE IS THE ACCELERATION OF MEDICAL GENOMICS TO BENEFIT PATIENTS AROUND THE WORLD. NYGC'S INNOVATION, RESEARCH AND QUALITY MAKE IT A UNIQUE AND STRONG COLLABORATIVE PARTNER IN GENOMICS. NYGC'S SCIENTIFIC MISSION BUILDS ON</p>

990 Schedule O, Supplemental Information

Return Reference	Explanation
THE ORGANIZATIONS MISSION	<p>THE COLLABORATIVE RESEARCH PROJECTS AMONG NYGC FACULTY MEMBERS AND STAFF SCIENTISTS WITH SCIENTISTS AND CLINICIANS FROM MEMBER INSTITUTIONS, AN AFFILIATE MEMBERSHIP PROGRAM, DISEASE- AND TECHNOLOGY-CENTERED WORKING GROUPS AND INDUSTRY PARTNERS. IN 2019, NYGC CONTINUED TO EXPAND ITS AFFILIATE MEMBERSHIP PROGRAM, WHICH NOW TOTALS 80 MEMBERS, HAILING FROM 14 ACADEMIC INSTITUTIONS ACROSS THE COUNTRY. RESEARCH AND FACULTY ----- SINCE ITS INCEPTION, NYGC HAS ATTRACTED WORLD-CLASS SCIENTISTS WHOSE GENOMIC EXPERTISE - INCLUDING SINGLE CELL GENOMICS, GENOME ENGINEERING, POPULATION, FUNCTIONAL AND EVOLUTIONARY GENOMICS, TECHNOLOGY AND METHODS DEVELOPMENT, STATISTICS, COMPUTATIONAL BIOLOGY AND BIOENGINEERING - BRING A MULTIDISCIPLINARY AND IN-DEPTH APPROACH TO THE EVOLVING FIELD OF GENOMICS. NYGC'S FACULTY SUPPORT NYGC'S SCIENTIFIC VISION THROUGH THE ADVANCEMENT OF TECHNOLOGY DEVELOPMENT AND GENOMIC MEDICINE. FACULTY MEMBERS HAVE JOINT APPOINTMENTS AT THE NYGC'S INSTITUTIONAL FOUNDING MEMBERS TO PROMOTE COLLABORATION, STRENGTHEN RESEARCH CAPABILITIES, ADVANCE ACADEMIC LEADERSHIP, AND ENHANCE OUR ABILITY TO UNDERSTAND AND HELP TREAT HUMAN DISEASES. IN 2019, NYGC MANAGED 56 GRANTS FROM THE NATIONAL INSTITUTES OF HEALTH (NIH). NYGC'S RESEARCHERS ARE WORKING WITH ITS MEMBER INSTITUTIONS AND COLLABORATIVE PARTNERS TO ADDRESS THE FUNDAMENTAL CHALLENGE IN PRECISION MEDICINE: UNDERSTANDING THE RELATIONSHIP BETWEEN DNA SEQUENCE VARIATION AND MECHANISMS OF HUMAN DISEASE, RANGING FROM CANCER TO AUTISM TO NEURODEGENERATIVE DISEASE. NYGC RESEARCHERS PUBLISHED MORE THAN 50 STUDIES IN LEADING SCIENTIFIC JOURNALS IN 2019, FUELING MOMENTUM FOR IMPORTANT COLLABORATIVE WORK. THEY COMPLETED 490 PROJECTS, AND COLLABORATED WITH 131 INVESTIGATORS FROM 92 INSTITUTIONS WORLDWIDE. NYGC FACULTY MEMBERS FOCUS THEIR RESEARCH ON THE DEVELOPMENT AND APPLICATION OF ADVANCED GENOMICS TO UNDERSTAND DISEASE.</p>

990 Schedule O, Open Information

Return Reference	Explanation
PROGRAM SERVICE ACCOMPLISHMENTS	<p>ACCOMPLISHMENTS IN 2019 INCLUDE: NEURODEGENERATIVE DISEASE ----- GROUND BREAKING ALS GENE EXPRESSION ATLAS REVEALED NEW INSIGHTS INTO DISEASE PROGRESSION: RESEARCHERS AT THE NYGC LED THE GLOBAL COLLABORATION THAT DEVELOPED A MULTIDIMENSIONAL GENE EXPRESSION ATLAS THAT OFFERS A PREVIOUSLY UNAVAILABLE VIEW OF DISEASE PROGRESSION IN ALS. UTILIZING SPATIAL TRANSCRIPTOMICS TECHNOLOGY, COMBINED WITH A NOVEL COMPUTATIONAL APPROACH, THE TEAM IDENTIFIED EARLY CHANGES NOT OBSERVABLE USING TRADITIONAL SEQUENCING METHODS. THEIR FINDINGS, PUBLISHED IN SCIENCE IN APRIL 2019, REVEALED NEW INSIGHTS INTO DISEASE SIGNALING PATHWAYS, SUGGESTED NEW TARGET OPPORTUNITIES FOR DESIGNING THERAPEUTICS AND TREATMENTS, AND WILL PROVIDE A FRAMEWORK FOR FURTHER MAPPING AND BETTER UNDERSTANDING OF THE DISEASE MECHANISMS OF OTHER NEURODEGENERATIVE DISEASES WITH COMMON PATHWAYS. HEMALI PHATNANI, PHD, DIRECTOR OF NYGC'S CENTER FOR GENOMICS OF NEURODEGENERATIVE DISEASE (CGND), IS SENIOR AUTHOR OF THE STUDY AND SILAS MANIATIS, PHD, STAFF SCIENTIST, IS CO-FIRST AUTHOR. THEIR COLLABORATORS INCLUDED SCIENTISTS FROM THE SIMONS FOUNDATION'S FLATIRON INSTITUTE IN NEW YORK, THE SCILIFELAB AND KTH ROYAL INSTITUTE OF TECHNOLOGY IN SWEDEN, AND NEW YORK UNIVERSITY. NYGC'S CGND'S DEVELOPMENT OF THE ALS CONSORTIUM, A GLOBAL COLLABORATION OF CLINICIANS, SCIENTISTS, GENETICISTS, AND COMPUTATIONAL BIOLOGISTS, HAS RAPIDLY GROWN OVER THE LAST FIVE YEARS TO INCLUDE MORE THAN 30 MEMBER INSTITUTIONS IN COUNTRIES AROUND THE WORLD. THE RESULTS ALS DATA SHARING ON AN UNPARALLELED AND UNPRECEDENTED SCALE, EMPOWERING AN INTEGRATED WORLDWIDE APPROACH TO WORKING TOWARD NEW TREATMENTS AND EFFECTIVE THERAPIES FOR ALS. IN 2019, THE CGND'S COLLABORATIVE APPROACH CONTRIBUTED TO THESE SIGNIFICANT ADVANCES IN ALS RESEARCH: * A BREAKTHROUGH STUDY LED BY COLD SPRING HARBOR LABORATORY ASSOCIATE PROFESSOR MOLLY GALE HAMMELL, PHD, PUBLISHED IN CELL, REPORTED IN OCTOBER 2019, THAT IDENTIFIED THAT TDP-43 PROTEINS ARE DYSFUNCTIONAL IN ALS, CAUSING DE-SILENCING OF RETROTRANSPOSONS, KNOWN AS "JUMPING GENES." THE STUDY USED THE NYGC ALS CONSORTIUM COHORT OF ALS PATIENT SAMPLES AS PART OF ITS DATA ANALYSIS. THE SCIENTISTS NOW SEEK TO CONFIRM WHETHER HIGH LEVELS OF THESE GENES MIGHT MIMIC A VIRAL PATHOGEN OR OTHER INFECTION IN THE TISSUES. IF SO, THESE GENES MAY BE DIRECTLY TARGETED WITH ANTIVIRAL AGENTS OR OTHER THERAPIES. DR. PHATNANI AND MEMBERS OF HER LAB ARE AMONG THE STUDY CO-AUTHORS. DR. HAMMELL IS A MEMBER OF THE NYGC'S NEURODEGENERATIVE DISEASE SCIENTIFIC WORKING GROUP. * OTHER RECENT GENETIC ASSOCIATIONS OR MAJOR VALIDATIONS OF ALS GENES USING NYGC ALS CONSORTIUM DATA INCLUDED THE IDENTIFICATION OF PKP4 AND LGALS1 IN APRIL 2019 (PUBLISHED IN GENOME RESEARCH) AND KIF5A IN MARCH 2018 (PUBLISHED IN NEURON). * DR. PHATNANI IS ALSO A CO-AUTHOR OF THE MASSACHUSETTS GENERAL HOSPITAL/HARVARD MEDICAL SCHOOL-LED STUDY, PUBLISHED IN NATURE NEUROSCIENCE IN NOVEMBER 2019, THAT IDENTIFIED DNAJC7 AS A NOVEL GENE</p>

990 Schedule O, Organizational Information

Return Reference	Explanation
PROGRAM SERVICE ACCOMPLISHMENTS	<p>IMPLICATED IN ALS. NEUROPSYCHIATRIC DISEASE ----- THROUGH A \$40 MILLION GRANT AWARD FROM THE NATIONAL HUMAN GENOME RESEARCH INSTITUTE, A DIVISION OF NIH, IN 2015 THE NYGC CREATED A CENTER FOR COMMON DISEASE GENOMICS, WHICH IS ENGAGED IN LARGE-SCALE WHOLE GENOME SEQUENCING STUDIES OF AUTISM AND OTHER COMPLEX DISEASES. NYGC RESEARCHERS ARE INVOLVED IN SFARI (SIMONS FOUNDATION AUTISM RESEARCH INITIATIVE) AND SPARK (SIMONS FOUNDATION POWERING AUTISM RESEARCH FOR KNOWLEDGE) AND LEAD OR CONTRIBUTE TO AN ARRAY OF OTHER COLLABORATIVE NEUROPSYCHIATRIC DISEASE-RELATED GENOMIC STUDIES. KEY MILESTONES IN 2019 INCLUDE: 30,000 WHOLE GENOMES OF AUTISM PATIENTS AND THEIR FAMILIES SEQUENCED: THE SCALE OF THIS DATA SET, WHICH IS BEING SEQUENCED AND ANALYZED THROUGH NYGC'S CENTER FOR COMMON DISEASE GENOMICS, REACHED THIS MILESTONE BY YEAR-END 2019. IT IS ONE OF THE LARGEST DATASETS AVAILABLE FOR RESEARCHERS TO STUDY AND IS HELPING TO UNCOVER NEW INSIGHTS INTO AUTISM. NEW AUTISM RISK GENE VARIANTS IDENTIFIED: IN AUGUST 2019, SPARK RELEASED ITS PILOT STUDY, AN ANALYSIS OF EXOME SEQUENCING OF 457 AUTISM FAMILIES. THE RESEARCH TEAM INCLUDED EVAN EICHLER, PHD, UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE, AND ASSOCIATE MEMBER, NYGC, AND WAS LED BY WENDY CHUNG, MD, PHD, COLUMBIA UNIVERSITY, AND AFFILIATE MEMBER, NYGC. THROUGH THEIR ANALYSIS, THE RESEARCHERS IDENTIFIED 647 RARE VARIANTS THAT WERE PRESENT FOR THE FIRST TIME IN A FAMILY MEMBER, EITHER AS A RESULT OF A MUTATION IN THE EGG OR SPERM OF ONE OF THE PARENTS, OR A VARIANT THAT ARISES IN THE FERTILIZED EGG. THEY ALSO FOUND INDELS, WHICH ARE INSERTIONS OR DELETIONS OF BASES IN THE GENOME, THAT APPEARED AT HIGHER FREQUENCY IN THOSE WITH AUTISM AS COMPARED TO THOSE WITHOUT AUTISM. MANY OF THESE VARIANTS WERE PREVIOUSLY KNOWN TO BE ASSOCIATED WITH AUTISM, WHILE OTHERS EMERGED FOR THE FIRST TIME. THEIR STUDY WAS PUBLISHED IN NPJ GENOMIC MEDICINE. THE NEXT PHASE OF THE SPARK PROJECT WILL LEVERAGE THE WHOLE GENOME SEQUENCING AND ANALYSIS OF SOME 1,600 AUTISM FAMILIES, CONDUCTED BY NYGC RESEARCHERS. REPORTS ON THESE FINDINGS ARE EXPECTED TO BE RELEASED THROUGHOUT 2020. NIH GRANT TO STUDY SCHIZOPHRENIA/BIPOLAR/AUTISM DISEASE RISK: NYGC CORE FACULTY MEMBER TUULI LAPPALAINEN, PHD, WHO HOLDS A JOINT APPOINTMENT AT COLUMBIA UNIVERSITY, RECEIVED RENEWED NIH R01 FUNDING SUPPORT IN AUGUST 2019 FOR A PROJECT TITLED "INTEGRATIVE ANALYSIS OF GENETIC VARIATION AND TRANSCRIPTION FACTOR NETWORKS TO ELUCIDATE MECHANISMS OF MENTAL HEALTH DISORDERS." HER PROJECT, A COLLABORATION WITH COLUMBIA UNIVERSITY COLLEAGUE HARMEN BUSSEMAKER, PHD, WILL DEPLOY NUMEROUS LARGE-SCALE FUNCTIONAL GENOMIC DATA SETS AS WELL AS EXPERIMENTAL APPROACHES TO EXPLORE SCHIZOPHRENIA, BIPOLAR DISEASE AND AUTISM RISK. EXPANDED NEUROPSYCHIATRIC GENOMICS LEADERSHIP: IN FALL 2019, NYGC ANNOUNCED THE APPOINTMENT OF THOMAS LEHNER, PHD, MPH, AS SCIENTIFIC DIRECTOR OF NEUROPSYCHIATRIC DISEASE GENOMICS. DR. LEHNER JOINED NYGC AFTER A DISTINGUISHED 15-YEAR T</p>

990 Schedule O, Supplemental Information

Return Reference	Explanation
PROGRAM SERVICE ACCOMPLISHMENTS	<p>ENURE AT THE NATIONAL INSTITUTE OF MENTAL HEALTH (NIMH), A DIVISION OF NIH, WHERE HE WAS INSTRUMENTAL IN THE CONCEPTION AND DEVELOPMENT OF THE NIMH'S COMPREHENSIVE NEUROPSYCHIATRIC GENOMICS PROGRAM. DR. LEHNER IS DEVELOPING AND SPEARHEADING THE OVERARCHING SCIENTIFIC STRATEGY FOR NYGC'S NEUROPSYCHIATRIC DISEASE GENOMICS RESEARCH. INTERNATIONALLY RENOWNED GENETICIST MARY-CLAIRE KING, PHD, JOINED NYGC'S FACULTY ON A CONSULTING BASIS AS SENIOR ASSOCIATE CORE MEMBER IN NOVEMBER 2019. DR. KING IS THE AMERICAN CANCER SOCIETY PROFESSOR IN THE DEPARTMENTS OF GENOME SCIENCES AND MEDICINE AT THE UNIVERSITY OF WASHINGTON. SHE WAS THE FIRST TO SHOW THAT BREAST AND OVARIAN CANCER IS INHERITED IN SOME FAMILIES AS THE RESULT OF MUTATIONS IN THE GENE THAT SHE NAMED BRCA1, A DISCOVERY THAT HAS TRANSFORMED THE DIAGNOSIS, DRUG DEVELOPMENT AND TREATMENT OF THIS INHERITED FORM OF BREAST CANCER. MORE RECENTLY, DR. KING HAS FOCUSED ON THE GENETICS OF SCHIZOPHRENIA, CONTRIBUTING TO THE UNDERSTANDING OF COMPLEX DISEASE INHERITANCE. SHE WILL SUPPORT NYGC'S EFFORTS TO UNDERSTAND THE GENETIC BASIS OF PSYCHIATRIC DISORDERS.</p>

990 Schedule O, Supplemental Information

Return Reference	Explanation
CANCER	<p>----- GENOMICS-CENTERED INITIATIVES TO ADDRESS CANCER CARE CHALLENGES ARE A KEY FOCUS OF THE GENOME CENTER CANCER GROUP (GCCG), LED BY NOBEL LAUREATE HAROLD VARMUS, MD, SENIOR ASSOCIATE CORE MEMBER, NYGC, AND LEWIS THOMAS UNIVERSITY PROFESSOR OF MEDICINE, WEILL CORNELL MEDICINE, AND CHARLES SAWYERS, MD, CHAIR, HUMAN ONCOLOGY AND PATHOGENESIS PROGRAM, MARIE- JOSE AND HENRY R. KRAVIS CHAIR, MEMORIAL SLOAN KETTERING CANCER CENTER, AND AFFILIATE MEMBER, NYGC. WITHIN THE LAST TWO YEARS, THE GCCG, COMPOSED OF CLINICIANS AND CANCER RESEARCHERS FROM NYGC'S MEMBER INSTITUTIONS, INCLUDING SEVEN NCI-DESIGNATED CANCER CENTERS, HAS DEVELOPED TWO MAJOR MULTI-INSTITUTIONAL COLLABORATIONS. IN 2018, THE GROUP BEGAN WORK ON ITS POLYETHNIC-1000 PROJECT TO STUDY CANCER GENOMES OF UNDERSERVED, ETHNICALLY DIVERSE POPULATIONS. IN 2019, THE GCCG LAUNCHED THE VERY RARE CANCER CONSORTIUM, A NEW COLLABORATION TO HELP ADVANCE CLINICAL CARE FOR PATIENTS AFFECTED BY VERY RARE TUMOR TYPES. THESE PROJECTS ACHIEVED THE FOLLOWING PROGRESS MILESTONES IN 2019: POLYETHNIC-1000 ADVANCED TO EXTENSIVE PROSPECTIVE STUDY. AT AN OCTOBER 2019 RETREAT, RESEARCHERS SHARED THE FINDINGS OF THE POLYETHNIC-1000 PROJECTS RETROSPECTIVE ANALYSIS OF OVER 100 SEQUENCED TUMOR SAMPLES FROM PATIENTS, COVERING CANCER TYPE, FREQUENCY OF GENETIC VARIATION, AND AN ESTIMATION OF GENETIC ANCESTRY. THE TEAM HAS FORGED STRONG CONNECTIONS BETWEEN ACADEMIC CENTERS AND PARTNER HOSPITALS AND IS NOW ADVANCING TO THE STUDY'S NEXT PHASE, AN EXTENSIVE PROSPECTIVE STUDY OF PATIENTS. STUDY FINDINGS WILL BE STORED IN A DATABASE THAT WILL SERVE AS A GLOBAL RESOURCE FOR DEVELOPING HYPOTHESES AND UNDERSTANDING OF ETHNIC AND RACIAL DIVERSITY IN CANCER. WHERE SEQUENCING REVEALS AN ACTIONABLE MUTATION IN THE TUMOR, THE STUDY TEAM WILL VALIDATE THE RESULTS CLINICALLY AND SHARE THE INFORMATION WITH THE TREATING PHYSICIAN. THE VERY RARE CANCER CONSORTIUM LAUNCHED ITS MULTI-INSTITUTIONAL MOLECULAR TUMOR BOARD WHERE ONCOLOGISTS, HEMATOLOGISTS, SCIENTISTS, PATHOLOGISTS, COMPUTATIONAL BIOLOGISTS, AND OTHER MEMBERS OF THE CANCER GENOMICS COMMUNITY ARE CONVENING AT THE NYGC ON A REGULAR BASIS TO HOLD MULTIDISCIPLINARY MOLECULAR TUMOR BOARD MEETINGS. CLINICIANS FROM PARTICIPATING HOSPITALS REPORT CASE CONFERENCES TO THE TUMOR BOARD TO DETERMINE THE MOST EFFECTIVE TREATMENT FOR PATIENTS WITH VERY RARE CANCERS. DR. VARMUS AND OLIVIER ELEMENTO, PHD, DIRECTOR, ENGLANDER INSTITUTE FOR PRECISION MEDICINE, WEILL CORNELL MEDICINE, AND AFFILIATE MEMBER, NYGC, ARE CO-LEADING THE CONSORTIUM AND ITS TUMOR BOARD. AN NYGC SEQUENCING TEST LED TO NEW INSIGHTS INTO PANCREATIC CANCER AND IMPROVED TREATMENT FOR A PANCREATIC CANCER PATIENT IN 2019. CLINICIANS USED NYGC CLINICAL LABS WHOLE GENOME AND TRANSCRIPTOME SEQUENCING (WGTS) ONCOLOGY TEST TO INFORM THEIR TREATMENT PLAN FOR A PATIENT WITH PANCREATIC CANCER. THE WGTS ANALYSIS OF THE PATIENT'S TUMOR GENOME IDENTIFIED A VARIANT THAT HAS BEEN SHOWN IN PRE-CLINICAL STUDIES TO BE SENSITIVE TO THE BRAF INHIBITOR</p>

990 Schedule O, Supplemental Information

Return Reference	Explanation
CANCER	<p>R DRUG DABRAFENIB. BASED ON THIS FINDING, CLINICIANS PROCEEDED TO TREAT THE PATIENT WITH D ABRAFENIB. OVERALL, THE PATIENTS CLINICAL CONDITION IMPROVED SIGNIFICANTLY, WITH DABRAFENI B-INDUCED REMISSION LASTING FOR SIX MONTHS. THE PAPER ON THE CASE WAS PUBLISHED IN MOLECULAR CASE STUDIES IN SEPTEMBER 2019. NYGC SCIENTIST KAZ WRZESZCZYNSKI, PHD, ASSISTANT DIRECTOR, CLINICAL ONCOLOGY INFORMATICS, NYGC, IS CO-CORRESPONDING AUTHOR ON THE PAPER ON THE PANCREATIC CASE WITH SCOTT POWERS, PHD, AND MINSIG CHOI, MD, OF STONY BROOK CANCER CENTER, WITH OTHER NYGC SCIENTISTS FROM THE NYGC CLINICAL LAB AND BIOINFORMATICS AND SEQUENCING TEAMS AMONG THE CO-AUTHORS. TECHNOLOGY INNOVATION ----- THE NEW GENOMICS TOOL ECCITE-SEQ DEVELOPED AT THE NYGC EXPANDED MULTIMODAL SINGLE CELL ANALYSIS. "INTERROGATION OF SINGLE CELLS TAKEN ONE STEP FURTHER," IS HOW ONE MEDIA OUTLET HERALDED THE SPRING 2019 RELEASE OF ECCITE-SEQ, WHICH EXTENDS CITE-SEQ, THE POWERFUL SINGLE-CELL ANALYSIS TOOL DEVELOPED BY NYGC SCIENTISTS IN 2017, FOR USE IN COMBINATION WITH EXPLORATORY CRISPR GENE EDITING SCREENS. THE EXPANDED TECHNOLOGY WAS DEVELOPED IN A COLLABORATION LED BY THE NYGC TECHNOLOGY INNOVATION LAB WITH THE LABS OF NYGC CORE FACULTY MEMBERS NEVILLE SANJANA, PHD, AND RAHUL SATIJA, PHD, WHO HOLD JOINT APPOINTMENTS AT NYU, AND RESEARCHERS FROM THE JACKSON LABORATORY. THE TEAMS REPORT ON THE TOOL, PUBLISHED IN NATURE METHODS IN APRIL AND FEATURED ON ITS MAY 2019 COVER, INCLUDES DEMONSTRATING ECCITE-SEQS ABILITY TO FINELY DISSECT SPECIFIC CELL SUBTYPES AND CHARACTERIZE MALIGNANT POPULATIONS IN A SAMPLE FROM A PATIENT WITH CUTANEOUS T CELL LYMPHOMA. ECCITE-SEQ HAS RAPIDLY BEEN ADOPTED BY RESEARCHERS THROUGHOUT THE WORLD, DEMONSTRATING ITS IMPORTANT IMPACT AND UTILITY TO THE FIELD. FURTHER ADVANCES ON GENOMIC TESTS AND TOOLS WERE MADE IN 2019. THE CANCER ANALYSIS TOOL GENOTYPING OF TRANSCRIPTOMES, DEVELOPED IN A COLLABORATION JOINTLY SUPERVISED BY NYGC CORE FACULTY MEMBER DAN LANDAU, MD, PHD, AND NYGC TECHNOLOGY INNOVATION LAB SENIOR MANAGER PETER SMIBERT, PHD, ENABLES MEASUREMENT OF GENE MUTATIONS AND THEIR EFFECTS ON GENE ACTIVITY WITHIN INDIVIDUAL CANCER CELLS BIOPSIED FROM PATIENTS. THE TEAMS STUDY WAS PUBLISHED IN NATURE IN JULY 2019. ANEVA (ANALYSIS OF EXPRESSION VARIATION), A NEW METHOD TO HELP DIAGNOSE RARE DISEASE, WAS DEVELOPED IN A STUDY SUPERVISED BY NYGC CORE FACULTY MEMBER TUULI LAPPALAINEN, PHD. THE METHOD FIRST TAKES DATA FROM A LARGE REFERENCE SAMPLE OF HEALTHY INDIVIDUALS. THEN, USING THE ANEVA DOSAGE OUTLIER TEST, RESEARCHERS WERE ABLE TO DIAGNOSE ADDITIONAL PATIENTS WHERE PREVIOUS METHODS OF GENOME AND RNA ANALYSIS HAD FAILED TO IDENTIFY THEIR RARE DISEASE VARIANTS. THE STUDY WAS PUBLISHED IN SCIENCE IN OCTOBER 2019. NYGC'S CLINICAL LABS CLINICAL CONSTITUTIONAL WHOLE-GENOME SEQUENCING (WGS) TEST, RECEIVED NEW YORK STATE DEPARTMENT OF HEALTH APPROVAL AT YEAR-END 2019. THIS TEST OFFERS PHYSICIANS THE MOST COMPLETE PACKAGE OF GENOMIC DATA AVAILABLE.</p>

990 Schedule O, Supplemental Information

Return Reference	Explanation
CANCER	ILABLE FOR PATIENTS WITH UNDIAGNOSED DISEASES, AS WELL AS THOSE PATIENTS WHO ARE SEEKING P REDISPOSITIONAL GENETIC TESTING. THE NYGC BIOINFORMATICS TEAM COLLABORATED ON THE DEVELOPM ENT OF AN INNOVATIVE GENOMIC TOOL IN 2017 EXPANSION HUNTER THAT IS USED IN THE WHOLE GENOM E SEQUENCING TEST. IT ENABLES THE ANALYSIS OF GENETIC VARIATION IN SHORT TANDEM REPEAT REG IONS OF THE GENOME.

990 Schedule O, Supplemental Information

Return Reference	Explanation
RESEARCH SEQUENCING	<p>----- NYGC HAS ONE OF THE LARGEST VOLUME WHOLE GENOME SEQUENCING PROGRAMS IN NEW YORK. IN THE PAST SIX YEARS, NYGC'S SEQUENCING LABORATORY HAS SEQUENCED OVER 77,000 WHOLE GENOME SAMPLES. NYGC HAS FIVE NOVASEQ SYSTEMS SEQUENCERS, WITH THE CAPACITY TO SEQUENCE OVER 40,000 GENOMES A YEAR. THIS STATE-OF-THE-ART SEQUENCING TECHNOLOGY ENABLES NYGC TO CONDUCT LARGE-SCALE GENOMICS PROJECTS WITH GREAT SPEED AND SAMPLE VOLUMES, AND TO EXPLORE THE GENOME IN MORE DEPTH WITH GREATER EFFICIENCY. NYGC'S RESEARCH SEQUENCING LAB, LED BY SOREN GERMER, PHD, SENIOR VICE PRESIDENT OF GENOME TECHNOLOGIES, PROCESSED MORE THAN 16,000 SAMPLES IN 2019, INCLUDING 12,262 WHOLE GENOME SEQUENCING SAMPLES (GERMLINE AND CANCER), 2,350 EXOME SEQUENCING SAMPLES, AND 2,200 TRANSCRIPTOME (RNA) SEQUENCING SAMPLES. OUR SUCCESS RATE FOR PASSING FLOW CELLS LANES ON THE NOVASEQ WAS 99.8%, NOT INCLUDING INSTRUMENT OR REAGENT ISSUES. AMONG OTHER LARGE COLLABORATIVE PROJECTS, SINCE 2016 NYGC HAS BEEN AWARDED \$40 MILLION FROM THE NHGRI AS ONE OF THE CENTERS FOR COMMON DISEASE GENOMICS (CCDG) FOR WHOLE GENOME SEQUENCING. THROUGH THIS AWARD, THE NYGC HAS TAKEN ADVANTAGE OF ITS CLINICALLY FOCUSED, COLLABORATIVE STRUCTURE WITH AN EYE TOWARD ACHIEVING A COMPREHENSIVE UNDERSTANDING OF DIFFERENT TYPES OF COMMON DISEASES, WITH A CENTER-SPECIFIC FOCUS ON AUTISM. NYGC DECREASED THE PRICE PER GENOME BY OVER 25% SINCE THE BEGINNING OF THE PROJECT THROUGH TECHNOLOGY INNOVATION AND AUTOMATION OF ALIGNMENT AND VARIANT CALLING PIPELINES. AS A MEMBER OF THIS MULTI-INSTITUTIONAL CONSORTIUM, THE NYGC LEADS AND ENABLES COLLABORATION, COMMUNICATION, AND ANALYSIS BETWEEN CENTERS AND PRINCIPAL INVESTIGATORS, PARTICIPATING IN NUMEROUS WORKING GROUPS, STEERING COMMITTEES, AND CONFERENCES AS WELL AS LEADING THE NEUROPSYCHIATRIC WORKING GROUP, WHICH SPANS THREE INSTITUTIONS AND SEVERAL DISORDERS. IN 2019, NYGC APPLIED FOR AND RECEIVED A 5TH YEAR OF FUNDING FOR THIS PROJECT, TO FURTHER THE WHOLE GENOME SEQUENCING RESEARCH ADVANCING OUR UNDERSTANDING OF AUTISM. BY THE COMPLETION OF THE PROJECT IN 2020, NYGC WILL HAVE SEQUENCED OVER 40,000 AUTISM GENOMES WITH SEVERAL PENDING PUBLICATIONS. IN 2019, NYGC ALSO RECEIVED SUPPLEMENTAL FUNDS TO SEQUENCE THE 2,504 PHASE 3 PANEL 1000 GENOMES SAMPLES TO HIGH COVERAGE, CREATING A LARGE HIGH QUALITY OPEN-SOURCE DATASET OF THESE DIVERSE REFERENCE SAMPLES FREELY AVAILABLE TO THE GENOMICS RESEARCH COMMUNITY.</p>

990 Schedule O, Organizational Information

Return Reference	Explanation
EDUCATION	<p>----- AS PART OF NYGC'S EDUCATIONAL MISSION, IT HOSTED MANY SCIENTIFIC MEETINGS, WORKS HOPS, CONFERENCES AND LECTURES IN 2019. THE NYGC GENOME CENTER CANCER GROUP ORGANIZES THE NEW YORK CANCER GENOMICS RESEARCH NETWORK MEETINGS THAT ARE HELD ON THE FIRST TUESDAY OF EVERY MONTH DURING THE ACADEMIC YEAR, BRINGING TOGETHER LEADING RESEARCHERS AND CLINICIANS FROM NYGC MEMBER AND OTHER ACADEMIC AND COMMUNITY-BASED INSTITUTIONS. THE MEETINGS ARE INTENDED PRIMARILY FOR PRINCIPAL INVESTIGATORS AND THEIR TRAINEES IN THE NEW YORK REGION. IN 2019, FIVE NEW SCIENTIFIC WORKING GROUPS WERE ESTABLISHED AT THE NYGC: NEURODEGENERATIVE DISEASE; NEUROPSYCHIATRIC DISEASE, COMPUTATIONAL CANCER GENOMICS; POPULATION GENOMICS; AND ENABLING INNOVATION. THESE NEW GROUPS, ALONG WITH NYGC'S FOUNDING WORKING GROUP, THE GENOME CENTER CANCER GROUP, ARE FORUMS FOR DISCUSSING CURRENT RESEARCH ADVANCES, TECHNICAL AND CONCEPTUAL CHALLENGES TO FURTHER PROGRESS, AND THE ESTABLISHMENT OF JOINT PROJECTS AND FUNDING STRATEGIES. NYGC'S BIOINFORMATICS TEAM HELD ITS FIFTH SEQUENCING INFORMATICS WORKSHOP IN FALL 2019. THE WORKSHOP OFFERS A MIX OF LECTURES FROM EXPERTS IN THE FIELD AND HANDS-ON EXERCISES TO STUDENTS EARLY IN THEIR TRAINING OR CAREER WHO HAVE PROJECTS INVOLVING NEXT GENERATION SEQUENCING. NYGC HELD "EVENING TALKS," A LECTURE SERIES FOR THE GENERAL PUBLIC ON ADVANCES IN GENOMIC SCIENCE, SPONSORED BY THE NEW YORK CITY COMMUNITY TRUST-PYEWACKET FUND. THESE TALKS ARE DESIGNED TO MAKE THE LATEST GENOMIC RESEARCH DISCOVERIES MORE ACCESSIBLE AND UNDERSTANDABLE FOR THE GENERAL PUBLIC. THESE WELL-ATTENDED LECTURES (AVERAGING 150 GUESTS PER EVENT) FEATURE PANELS OF LEADING RESEARCHERS AND CLINICIANS FROM NYGC AND/OR MEMBER INSTITUTIONS. IN 2019, NYGC HELD TALKS ON RARE DISEASE GENOMICS, THE LATEST ADVANCES IN DNA ANALYSIS, AND SPACE GENOMICS. NYGC HOSTED "FIVE POINTS" LECTURES FOR THE SCIENTIFIC COMMUNITY, FEATURING LEADING RESEARCHERS FROM AROUND THE COUNTRY AND ABROAD. THESE LECTURES BRING LEADING SCIENTISTS TO NYGC FOR IN-DEPTH DISCUSSIONS OF THEIR WORK WITH RESEARCHERS, CLINICIANS, AND STUDENTS FROM NYGC, ITS MEMBER INSTITUTIONS, AND OTHERS IN THE SCIENTIFIC COMMUNITY. ORGANIZATION MEMBERS FORM 990, PART VI, SECTION A, LINE 6: AS OF DECEMBER 31, 2019, THE CENTER HAD A TOTAL OF 19 MEMBERS, CONSISTING OF 12 INSTITUTIONAL FOUNDING MEMBERS AND SEVEN ASSOCIATE MEMBERS. *THE INSTITUTIONAL FOUNDING MEMBERS ARE THE FOLLOWING RECOGNIZED ACADEMIC, MEDICAL AND RESEARCH INSTITUTIONS: (1) COLD SPRING HARBOR LABORATORY, (2) CORNELL UNIVERSITY/WEILL CORNELL MEDICINE, (3) THE JACKSON LABORATORY, (4) MEMORIAL SLOAN-KETTERING CANCER CENTER, (5) ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, (6) NEW-YORK-PRE-SBYTERIAN HOSPITAL, (7) NEW YORK UNIVERSITY, SCHOOL OF MEDICINE, (8) NORTHWELL HEALTH, (9) THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK, ON BEHALF OF STONY BROOK UNIVERSITY, (10) THE ROCKEFELLER UNIVERSITY, (11) THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK, AND (12) ALBERT</p>

990 Schedule O, Supplemental Information

Return Reference	Explanation
EDUCATION	EINSTEIN COLLEGE OF MEDICINE. *ASSOCIATE MEMBERS: (1) AMERICAN MUSEUM OF NATURAL HISTORY, (2) HOSPITAL FOR SPECIAL SURGERY, (3) THE NEW YORK STEM CELL FOUNDATION, (4) ROSWELL PARK CANCER INSTITUTE, (5) PRINCETON UNIVERSITY, (6) HACKENSACK MERIDIAN HEALTH, AND (7) GEORGE TOWN LOMBARDI COMPREHENSIVE CANCER CENTER.

990 Schedule O, Supplemental Information

Return Reference	Explanation
ORGANIZATION MEMBERS - DECISION MAKING	FORM 990, PART VI, SECTION A, LINE 7A & 7B: EACH INSTITUTIONAL FOUNDING MEMBER APPOINTS ONE REPRESENTATIVE TO SERVE ON NYGC'S BOARD OF DIRECTORS. THE BOARD OF DIRECTORS ALSO INCLUDES THE SCIENTIFIC DIRECTOR AND OTHER DESIGNATED DIRECTORS OR INDIVIDUALS APPOINTED BY THE BOARD. DECISIONS REQUIRING BOARD APPROVAL INCLUDE THE ADMISSION OF NEW MEMBERS, CHANGES TO THE MISSION, CERTIFICATE OF INCORPORATION, AND BYLAWS, APPOINTMENT OR REMOVAL OF THE CHAIRPERSON OF THE BOARD AND THE SCIENTIFIC DIRECTOR, AND ADOPTION OF CERTAIN POLICIES AND PROCEDURES. THE BOARD ALSO REVIEWS AND APPROVES THE ANNUAL OPERATING BUDGET. MANAGEMENT HAS THE ABILITY TO ENTER INTO BUSINESS ARRANGEMENTS AND CONTRACTS, INCLUDING FINANCING ARRANGEMENTS.

990 Schedule O, Supplemental Information

Return Reference	Explanation
FORM 990 REVIEW	FORM 990, PART VI, SECTION B, LINE 11: THE FORM 990 IS PREPARED BY AN INDEPENDENT PUBLIC ACCOUNTING FIRM, UTILIZING INFORMATION PROVIDED BY MANAGEMENT. UPON RECEIPT OF THE DRAFT FORM 990, MANAGEMENT, INCLUDING THE DIRECTOR OF FINANCE; GENERAL COUNSEL; AND PRESIDENT & COO, REVIEW THE FORM. PRIOR TO FILING, MANAGEMENT PRESENTS THE FORM 990 TO THE AUDIT COMMITTEE OF THE BOARD FOR REVIEW AND COMMENT. ALSO PRIOR TO FILING, MANAGEMENT PROVIDES THE FORM 990 TO THE ENTIRE BOARD OF DIRECTORS.

990 Schedule O, Supplemental Information

Return Reference	Explanation
CONFLICT OF INTEREST POLICY & REVIEW	FORM 990, PART VI, SECTION B, LINE 12C: NYGC REQUIRES ALL INTERESTED PERSONS (DEFINED AS BOARD MEMBERS, PRINCIPAL OFFICERS, OR MEMBERS OF A COMMITTEE TO WHICH THE BOARD HAS DELEGATED POWERS) TO DISCLOSE CONFLICTS OF INTEREST AS REQUIRED BY THE CONFLICT OF INTEREST POLICY. NYGC FOLLOWS A PROCEDURE FOR OBTAINING SUCH DISCLOSURES ANNUALLY. ANY POTENTIAL CONFLICTS OF INTEREST MUST BE REVIEWED BY THE BOARD. IF AN INTERESTED PERSON HAS A POTENTIAL CONFLICT OF INTEREST, HE OR SHE MAY MAKE A PRESENTATION AT THE BOARD OR COMMITTEE MEETING, BUT AFTER SUCH PRESENTATION, HE/SHE SHALL LEAVE THE MEETING DURING THE DISCUSSION OF, AND THE VOTE ON, THE TRANSACTION OR ARRANGEMENT THAT CREATES THE POTENTIAL CONFLICT OF INTEREST.

990 Schedule O, Supplemental Information

Return Reference	Explanation
COMPENSATION REVIEW AND APPROVAL	<p>FORM 990, PART VI, SECTION B, LINE 15: FOR THE ORGANIZATION'S TOP MANAGEMENT OFFICIAL, PLEASE REFER TO SCHEDULE J NARRATIVES FOR THE PROCESS OF DETERMINING COMPENSATION. IN LATE 2018 NYGC HIRED AN INDEPENDENT COMPENSATION CONSULTANT TO PERFORM AN EXECUTIVE TOTAL COMPENSATION STUDY OF SENIOR MANAGEMENT'S COMPENSATION. RESULTS OF THIS REVIEW WERE PROVIDED TO THE AD-HOC COMPENSATION COMMITTEE IN EARLY 2019 AND THE COMMITTEE DISCUSSED THEM. THE REVIEW SHOWED THAT THE COMPENSATION PAID TO ALL MEMBERS OF SENIOR MANAGEMENT (PRESIDENT AND COO, CHIEF BUSINESS OFFICER, SENIOR VICE PRESIDENT, FINANCE & ADMINISTRATION, SVP, GENOME TECHNOLOGIES, VICE PRESIDENT, DEVELOPMENT AND COMMUNICATIONS, VICE PRESIDENT & GENERAL COUNSEL, AND THE SCIENTIFIC DIRECTOR AND CEO) WAS REASONABLE. THE AD-HOC COMPENSATION COMMITTEE DISCUSSED SENIOR MANAGEMENT COMPENSATION IN EARLY 2019. THREE MEMBERS OF SENIOR MANAGEMENT RECEIVED MERIT INCREASES IN 2019 (PRESIDENT AND COO, VICE PRESIDENT & GENERAL COUNSEL, AND THE SCIENTIFIC DIRECTOR AND CEO), WHICH WERE APPROVED BY THE AD-HOC COMPENSATION COMMITTEE IN JANUARY 2019. WHILE THE SCIENTIFIC DIRECTOR & CEOS COMPENSATION IS SET BY AN UNRELATED ENTITY, THE AD-HOC COMPENSATION COMMITTEE COMMUNICATED WITH THE UNRELATED ENTITY TO APPROVE HIS MERIT INCREASE IN 2019. THE OTHER MEMBERS OF THE SENIOR MANAGEMENT TEAM DID NOT RECEIVE MERIT INCREASES IN 2019 AND THEIR COMPENSATION REMAIN UNCHANGED.</p>

990 Schedule O, Supplemental Information

Return Reference	Explanation
DOCUMENT DISCLOSURE	FORM 990, PART VI, SECTION C, LINE 19: NYGC'S GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND FINANCIAL STATEMENTS ARE AVAILABLE UPON REQUEST. COMPENSATION OF OFFICERS AND DIRECTORS FORM 990, PART VII, SECTION A IN 2019, THE SCIENTIFIC DIRECTOR & CEO, WAS EMPLOYED BY AN UNRELATED ENTITY AND LEASED TO NYGC TO DEVOTE 80% OF HIS TIME AND EFFORT TO SERVING AS NYGC'S SCIENTIFIC DIRECTOR AND CEO, AN OFFICER OF THE CORPORATION, AND AN ASSOCIATE MEMBER OF NYGC'S FACULTY, WITH RESPONSIBILITY FOR OVERSEEING NYGC'S RESEARCH PROGRAM AND FOR UNDERTAKING SUCH OTHER ACTIVITIES AS NYGC'S BOARD OF DIRECTORS REQUESTED FROM TIME TO TIME. THE SCIENTIFIC DIRECTOR & CEO DEVOTES 20% OF HIS TIME TO HIS DUTIES AT THE UNRELATED ENTITY, WHERE HE MAINTAINS A LABORATORY AND CONDUCTS INDEPENDENT, INVESTIGATOR-INITIATED RESEARCH PROJECTS.